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ABSTRACT
Nanoparticles (NPs) are poised to have a tremendous impact on the treatment of many
diseases, but their broad application is limited because currently they can only be
administered by parenteral methods. Oral administration of NPs is highly preferred because
of the convenience and compliance by patients, but remains a significant challenge because
of the barriers presented by the gastrointestinal tract. In particular, transport across the
intestinal epithelium limits efficient oral delivery of NPs.
The neonatal Fc receptor (FcRn) mediates IgG antibody transport across epithelial barriers.
It was discovered as the receptor in the neonatal intestine that transports IgG in breast milk
from mother to offspring. However, FcRn is expressed into adulthood at levels similar to
fetal expression. FcRn interacts with the Fc portion of IgG in a pH-dependent manner,
binding with high affinity at acidic (<6.5) but not neutral pH (7.4).
Targeting NPs to FcRn using IgG Fc fragments was hypothesized to enable orally
administered NPs to be transported across the intestinal epithelium. FcRn-targeted NPs
were formulated using poly(lactic acid)-b-polyethylene glycol (PLA-PEG) block copolymers
and engineered to have particle sizes less than 100 nm with IgG Fc conjugated to the
surface. Transepithelial transport of the NPs was first evaluated in an in vitro cell monolayer
transport model using Caco-2 cells. FcRn-targeted NPs were transported across the
monolayer at a rate twice that of non-targeted NPs. The transport rate was reduced
significantly when excess IgG was added along with the FcRn-targeted NPs.
Next, FcRn-targeted NPs were then evaluated using in vivo mouse models. Fluorescent
FcRn-targeted NPs were observed with fluorescent microscopy crossing the intestinal
epithelium and entering the lamina propria after oral administration. Using radiolabeled
NPs, orally administered FcRn-targeted NPs were detected in the liver, lungs, and spleen
with a mean absorption efficiency of 13.7% for FcRn-targeted NPs compared with only 1.2%
for non-targeted NPs.
Finally, insulin was encapsulated in the NPs to evaluate the FcRn-targeted NPs as a NP-
based therapeutic. In wild-type mice, orally administered FcRn-targeted NPs containing
insulin were able to generate a prolonged hypoglycemic response using a clinically relevant
insulin dose of 1.1 U/kg. The response was specifically due to FcRn, as studies in FcRn
knockout mice mitigated the enhanced response of the FcRn-targeted NPs.
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This technology has the potential to have an impact on the treatment of many diseases by
enabling NP-based therapies to be administered orally. In addition, the encapsulation of
drugs or biologics that are currently limited by low bioavailability into FcRn-targeted NPs
may enable markedly more efficient oral delivery of the therapies.
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Chapter 1. Introduction
1.1. MOTIVATION FOR ORAL DELIVERY
The revolution in biomedical research that has occurred over the last half-century has
resulted in an unprecedented understanding of the biological processes associated with
many diseases. With this knowledge, exciting new therapies are being developed that could
have a significant impact on disease treatments. Many of these new therapies are biological
in nature, such as peptide hormones, antibodies, growth factors, enzymes, vaccines, and
nucleic acids, and are known as biologics. In fact, more than 100 biologics have been
developed over the past 30 years to treat diseases ranging from cancer and diabetes to rare
genetic disorders, generating $48 billion in the US market in 2009 (1). By combining
biological understanding with engineering and materials science, nanoparticle (NP)-based
therapeutics are also being developed and are poised to have a major impact on the
treatment of many diseases including cancer (2), cardiovascular disease (3), and diabetes
(4). Several NP-based therapeutics are now entering clinical trials or have been approved for
use (2, 5, 6).
However, the overall impact of biologics- and NP-based therapeutics may be limited to a
narrow set of indications because administration is currently restricted to parenteral
methods. Many diseases that would benefit from biologics- or NP-based therapies are
chronic, requiring frequent treatments over a prolonged period of time. Injection-based
therapies can suffer from poor patient compliance and reduced efficacy due to the pain and
inconvenience associated with treatment regimens. Therefore, alternate routes of
administration, such as transdermal, nasal, buccal, pulmonary, and oral, are under
investigation as a means to improve these therapies. Of these alternate routes, oral is
considered the most desirable, especially for chronic diseases, because of the convenience
and improved compliance (7).
In clinical studies with cancer patients, most favor oral over intravenous chemotherapy
because of the increased convenience as long as efficacy is not compromised (8-10). The
convenience of taking medication at home is especially convenient for patients that lived far
from hospitals or clinics (11). Several trials have demonstrated that oral-based therapies can
be as efficacious as parenteral administration, but offer additional advantages as well. In
one clinical trial, oral administration of Tegafur-uracil (UFT) was compared with intravenous
administration of 5-fluorouracil (5-FU) for the treatment of metastatic colorectal cancer
(12). The oral administration was associated with decreased incidence of drug-related
adverse effects without comprising efficacy, possibly due to the lower Cmax (peak
concentration) and AUC (exposure) of the oral UFT treatment. In a clinical trial comparing
oral versus intravenous bisphosphonate therapies for children with osteogenesis
imperfecta, the efficacy of the two treatments was the same, but the intravenous method
required frequent hospitalizations that were expensive, time intensive, and required
intravenous access that was difficult in children with osteogenesis imperfecta because of
vascular fragility (13). In addition, the oral therapy resulted in bones that were more
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uniformly labeled during growth. Oral formulations have advantages for physicians as well,
providing flexibility and adaptability to tune the dosing schedule to individual patients
responses based on efficacy and toxicity (11). Without the intensive demands on staff
required by intravenous administrations, studies in the United Kingdom showed that
switching from intravenous to oral chemotherapy would allow a 7-fold increase in the
number of patients treated (14). Finally, reducing hospital or clinic visits as well as costs
associated by using oral formulations could reduce overall costs for cancer treatments (15-
17). Indeed, cost-benefit studies conducted in Europe and Canada examining oral versus
standard intravenous regimens for colorectal cancer suggest significant savings with the oral
route despite the higher cost of the orally formulated therapies (18). Therefore, one quarter
of all new chemotherapies being developed are now oral agents (8, 19, 20).
For biologics- and NP-based therapeutics, there is currently no commercial solution to the
problem of oral administration. In order for these therapies to have the greatest impact on
patients, new technologies need to be developed that enable these therapies to be
administered in a more convenient form for patients, preferably the oral route of
administration.
1.2. PHYSIOLOGY OF THE GASTROINTESTINAL TRACT
To achieve oral delivery, molecules must pass through the gastrointestinal (GI) tract and be
absorbed before entering the bloodstream. The GI tract consists of the oral cavity,
esophagus, stomach, small and large intestine. The small intestine plays the primary role in
regulating the absorption of material (Figure 1.1). It is well adapted for this role, with
macroscopic folds on the inner surface as well as microscopic finger-like projections called
villi that significantly increase the surface area for absorption. The functional unit of the
small intestine is the crypt-villus. The villi epithelium is a polarized cell monolayer that acts
as a barrier to tightly regulate the transport of material from the external environment
(intestinal lumen) to the lamina propria. The epithelial cells rest on top of a rich
extracellular matrix called the basal lamina that divides the epithelium from the lamina
propria. The lamina propria within each villus contains a network of capillary beds for
absorption of molecules transported across the epithelial barrier and a blunt-ended
lymphatic vessel called a lacteal for absorption of larger particles such as fats. The
capillaries converge into venules and, eventually, the hepatic vein that transports material
to the liver. The lymphatic vessels carry material through the lymph nodes before flowing
into the blood through the thoracic duct.
The intestinal epithelium consists of different cell types such as the absorptive enterocyte
cells, mucin-secreting goblet cells, endocrine cells, and Paneth cells (secrete lysozyme and
antimicrobial peptides) (Figure 1.2) (21). The absorptive enterocytes secrete digestive
enzymes and have hair-like projections on the apical membrane called microvilli that further
increase the absorptive surface area up to 300-400 m2 (22). Another cell type, M cells, are
only associated with Peyer's Patches, which are organized components of the gut-
associated lymphoid tissue (GALT). The role of M cells in the intestinal epithelium is to
transport antigens through a non-degradative pathway to dendritic cells in the Peyer's
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Patches, which can then activate B and T cells (23). M cells lack microvilli, do not secrete
mucus or digestive enzymes, and have a thinner glycocalyx, allowing for easier access to
antigens in the intestinal lumen.
1.3. CHALLENGES FOR ORAL DELIVERY
The challenges associated with oral delivery are due primarily to the number of barriers that
must be overcome in the GI tract before therapies are absorbed and enter the bloodstream.
These barriers include extreme pH environments, enzymatic degradation, and poor
permeability across the intestinal epithelium. The pH environments in the GI tract can range
from 1 in the stomach to 8 in parts of the intestine (24), which can cause pH-induced
oxidation, deamidation or hydrolysis of protein drugs, leading to loss of their activity (25).
Enzymatic degradation is due to proteases, nucleases, and lipases secreted to digest
biological molecules prior to absorption. GI proteases generally digest 94-98% of orally
administered proteins and produce smaller peptide fragments and amino acids that can be
absorbed by enterocytes (26). If these barriers are overcome, the molecules must then
reach the mucosal barrier for absorption in order to reach the bloodstream. The mucosal
barrier of the small intestine can be divided into extrinsic and intrinsic barriers (27).
The extrinsic barrier consists of the mucus layer covering the epithelial cells. The mucus
layer is a complex hydrogel material composed of proteins, carbohydrates, lipids, salts,
antibodies, bacteria, and cellular debris (28). The role of mucus is to protect epithelial
surfaces by trapping pathogens and foreign particulates and rapidly clearing them as well as
to lubricate the GI tract. The mucus barrier consists of a loosely adherent layer and a firmly
adherent layer that vary in thickness throughout the GI tract and can fluctuate based on diet
(Figure 1.3) (29). The firmly adherent layer near the surface of the epithelium is stagnant
and hydrophobic in nature (30, 31). Penetration of this mucus barrier is necessary in order
to reach the absorptive epithelial cells.
The intrinsic barrier consists of the epithelial cell monolayer itself, representing the major
restrictive barrier to passive diffusion of water, solutes, and microorganisms. The cells
maintain this barrier through the formation of tight junctions, which are fusions between
lateral membranes of adjacent cells (32). Through specific combinations of different
proteins, the permeability of the tight junctions can be modulated. The tight junctions are
most permeable at the proximal end of the small intestine and become increasingly
impermeable as molecules proceed through the intestines. Intestinal cells also have
metabolic systems and P-glycoprotein (P-gp) drug efflux pumps that can cause low
bioavailability for many small molecule drugs such as chemotherapeutic agents (33).
Another barrier intimately associated with the epithelium is the immune system. Numerous
types of immune cells patrol the lamina propria, including large numbers of T cells,
macrophages, dendritic cells, mast cells, and eosinophils (23). In addition, some immune
cells associate directly with epithelial cells. Intraepithelial lymphocytes (IEL) are unique T
cells that reside in the space between epithelial cells near the basolateral surface of the
epithelium. IEL have several roles, including playing a role in epithelial tumor surveillance,
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protection against epithelial pathogens, and promotion of healing of the gut after injury (34,
35). Dendritic cells are involved in the acquisition and processing of antigens from the
lumen. These cells can sample the lumen for antigens directly by extending pseudopods
through the space between epithelial cells into the lumen. Epithelial cells can also transport
antigens from the lumen across the cellular barrier and then transfer the antigens to
dendritic cells for processing (36).
Finally, molecules that are able to evade the immune system in the lamina propria and
enter the bloodstream must still overcome the mononuclear phagocyte system (MPS) of the
liver, while molecules that enter the lacteal must pass through lymph nodes before entering
the bloodstream.
1.4. INTESTINAL TRANSEPITHELIAL PATHWAYS
There are several pathways used by molecules to get across the epithelial cell barrier that
could be used for oral delivery (Figure 1.4) (37). The trancellular pathway passes through
the apical and basolateral cell membranes as well as the cytoplasm. This pathway is very
restrictive to the passive flow of hydrophilic solutes because of the lipid bilayer membrane
and is impermeable for molecules with a Stokes radii of >4 angstroms. Mechanisms of
transport for this pathway can be passive for hydrophobic molecules or active if a
membrane pump is present for specific molecules such as ions. The paracellular pathway is
the major transepithelial passive permeation pathway and allows diffusion of molecules in
the space between epithelial cells. The tight junctions regulate the permeability of this
pathway based on the size and charge of the molecules (32, 38). At the proximal end of the
small intestine, where the tight junctions are most permeable, molecules with a Stokes radii
of <11 angstroms can pass through the barrier. Transcytosis is an active transport pathway
that relies on receptors specific for a molecule to guide the molecule through the cell
without entering a degradation pathway. Because of their size, macromolecules, such as
biologics, and NPs are restricted to this pathway for transport across the cellular barrier.
1.5. STRATEGIES FOR ORAL DELIVERY
1.5.1. Protease inhibitors
There have been many different strategies tested for oral delivery, especially for the oral
delivery of biologics. One of the major barriers for delivery of biologics is the extensive
enzymatic degradation in the stomach and intestines. One strategy aimed at preventing
degradation is the use of enzyme inhibitors. Examples include aprotinin, soybean trypsin
inhibitor, and polycarbophil (39, 40). By administering insulin together with aprotinin and
soybean trypsin inhibitor, studies have shown that a hypoglycemic effect was induced (39).
However, there was a toxic potential associated with the use of protease inhibitors due to
the incomplete digestion of nutrients. In addition, inhibition can result in increased
secretion of digestive enzymes as a result of feedback regulation, leading to hypertrophy
and hyperplasia of the pancreas (40, 41).
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1.5.2. Permeation Enhancers
Permeation enhancers have been studied for their ability to increase intestinal epithelium
permeability either through the paracellular or transcellular transport pathways. Examples
of enhancers include compounds such as surfactants, fatty acids, bile salts, and chelators
such as EDTA (42). These substances increase the fluidity of the cell membrane lipid bilayer,
resulting in enhanced permeability. Gel-forming polymers, such as polycarbophil, can act as
permeation enhancers by binding extracellular Ca , which plays a role in the regulation of
tight junction permeability (43). Another molecule used as a permeation enhancer is zonula
occludens toxin, a protein secreted by Vibrio cholerae. Occludens are proteins associated
with the tight junctions. The toxin causes increased permeability by modifying the
cytoskeletal organization of the cells (44). Permeation enhancers have shown promise in
increasing transport across the intestinal barrier, but there are several issues that
potentially limit the clinical application of this strategy (7). Some enhancers can locally
damage the intestinal mucosa and potentially enter the systemic circulation, leading to
systemic toxic effects. The enhancers are also non-specific, which could allow toxins and
other biological pathogens to cross the intestinal barrier (45).
Permeation enhancer technology was being commercialized by Emisphere Technologies,
Inc. The enhancer, based on sodium N-[8-(2-hydroxybenzoyl)aminocaprylate] (SNAC),
interacted with drug molecules to create a non-covalent association (46, 47). Emisphere
claimed that SNAC did not cause damage to the intestinal epithelium unlike traditional
permeation enhancers (48). In proof of concept studies with Type I diabetic patients, an
insulin capsule containing 10 mg of insulin and 200 mg of SNAC was administered 30 min
prior to a standardized meal and resulted in reduced post-prandial excursion and a marked
increase in systemic insulin levels. However, the formulation caused nausea in patients and
had an impractical ratio of SNAC to insulin. Currently, the technology is no longer under
development by Emisphere.
1.5.3 Polymeric NPs
Polymeric NPs are a well-studied option for oral delivery that have several advantages over
other systems (49). The NPs are stable in the GI environment and can protect encapsulated
drugs from the pH environment, enzyme degradation, and drug efflux pumps (7, 50). For
example, when exposed to protease degradation, insulin and calcitonin stability was
improved through encapsulation in polymeric NPs (51, 52). Using polymers to form the NPs
provides considerable flexibility in NP design by enabling modulation of physicochemical
parameters (size, surface charge, hydrophobicity), drug release properties (controlled or
triggered), and surface properties (attachment of targeting ligands). The small size increases
the specific surface area, allowing increased contact area with the epithelial surface and a
greater potential for non-specific uptake or receptor-mediated endocytosis. Finally,
polymeric NPs can be composed of biodegradable materials that should reduce
accumulation of NPs following repeated dosing (53). However, intestinal absorption of NPs
is highly inefficient because the physicochemical parameters of NPs prevent their transport
across cellular barriers such as the intestinal epithelium. To improve the absorption
efficiency of NPs and make oral administration practical in the clinic, new strategies are
necessary to overcome the intestinal epithelial barrier.
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1.5.4. Mucoadhesives
Mucoadhesive materials for oral delivery applications are designed to increase the
residence time and contact of the released drug with the underlying epithelium, increasing
the drug concentration at the absorption site (54). However, if the mucoadhesive adheres
to the loosely adherent layer of mucus, it may be rapidly cleared from the intestine before
releasing most of the drug payload (55). Examples of mucoadhesive polymers include
poly(lactic acid) (PLA), poly(sebacic acid) (PSA), poly(lactic-co-glycolic acid) (PLGA) and
poly(acrylic acid) (PAA), which may achieve mucoadhesion via hydrogen bonding, polymer
entanglements with mucins, hydrophobic interactions, or a combination of these
mechanisms (56-58). One example of a mucoadhesive technology is complexation
hydrogels that change network structure in response to a stimuli such as pH, temperature,
or ionic strength (59). For oral delivery applications, pH-sensitive hydrogels have been
employed to entrap and protect drugs at low pH and release the drug at elevated pH by
swelling in response to the pH change. The polymeric material composing the hydrogels can
be engineered to exhibit mucoadhesive characteristics, resulting in release of the drug at
the site of adsorption (60). However, hydrogel particles have also been shown to reversibly
open the tight junctions to increase protein permeability across the intestinal barrier, which
introduces the same safety issues associated with permeation enhancers (61).
BioSante was developing calcium phosphate NPs for their BioOral system. The NPs consisted
of aggregated casein surrounding a core of PEG, calcium phosphate, and insulin. Casein is
non-degradable in acid and mucoadhesive. In a fasted diabetic mouse model, a single dose
of NPs administered directly into the stomach rapidly reduced the blood glucose levels by
80% within the first hour of treatment (62). However, at this point, the company is not
pursuing the technology for oral delivery applications.
1.5.5 Non-targeted NPs
NPs for oral delivery have been engineered for non-specific uptake by absorptive
enterocytes and M cells by optimizing particle size (63, 64), hydrophobicity (65), and surface
charge (66). M cells, in particular, have been focused on because they have reduced
protease activity and a relatively sparse glycocalyx surface relative to other epithelial cells
that allows for the adherence of both microorganisms and inert particles (67). This is
consistent with its biological function, which is to sample the intestinal lumen for pathogens
and transcytose molecules across the epithelial barrier for delivery to dendritic cells.
However, NPs transcytosed by M cells are exposed to the underlying immune cells, such as
dendritic cells and macrophages, that are likely to take up and process NPs before they can
reach the bloodstream (Figure 1.5) (68).
Particle size studies have generally indicated that smaller NPs (<50-100 nm) are taken up by
enterocytes, while larger NPs are more selectively taken up by M cells (55, 69). Optimization
of the surface charge has been more difficult, and it remains unclear exactly how surface
charge affects non-specific uptake by enterocytes or M cells. In one study, neutral NPs
ranging in size from 130 to 950 nm were identified as ideal for uptake by M cells (70).
Others have hypothesized that a positive charge would enhance interactions with the
negatively-charged surface of M cells. However, the negative charge of mucus could lead to
interactions with the NPs and prevent NPs from reaching the M cells (71).
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Surface modifications have also been used to optimize the NPs. Dense polyethylene glycol
(PEG) coating of the surface has been demonstrated to minimize interaction between NPs
and mucus, enabling penetration through the mucus barrier (72). Hydrophobicity is another
parameter that influences NP uptake, with studies suggesting that NPs formed using
hydrophobic polymers (polystyrene, polymethylmethacrylate, and polyhydroxybutrate) had
significantly more uptake by M cells than less hydrophobic lactide and glycolide polymer
particles (73). However, hydrophobicity could also enhance interactions with mucus, so
further optimization may be needed (28).
1.5.6. Targeted NPs
Targeted NP oral delivery strategies have focused on specifically targeting receptors on
enterocytes or M cells for receptor-mediated endocytosis or transcytosis. Targeted NPs
have ligands conjugated to the surface for specific interactions with receptors on cell
surfaces. After binding and receptor-mediated endocytosis, the receptor-ligand complex is
contained within a vesicle whose pathway through the cell is determined by the receptor.
Vesicles can be recycled back to the same membrane surface, directed toward lysosomes
through the degradation pathway of the cell, or transported across the cell using a
transcytosis pathway and released through exocytosis.
There are several different ligands that have been used to target receptors on enterocytes
and M cells. One example is lectins, a class of proteins that specifically bind to
carbohydrates and have been investigated for receptor-mediated oral delivery because of
their resistance to acidic pH and proteases as well as having a large number of binding sites
on the glycocalyx of epithelial cells (74, 75). Studies with tomato lectin-conjugated NPs have
shown that targeted NPs are resistant to digestion, increase bioadhesion through mucus
interactions (76, 77), and increase endocytosis through enhanced interactions with
epithelial cells (78, 79). Another lectin is wheat germ agglutinin (WGA), which binds to N-
acetyl-glucosamine and sialic acid found throughout the GI tract (80). Studies with WGA
demonstrated that it not only binds to the surface of enterocytes, but is taken up into cells
by receptor-mediated endocytosis through the epidermal growth factor receptor that is
highly expressed on enterocytes (81). However, lectins have not been shown to traffic
through a transcytosis pathway. Therefore, NPs taken up either remain on the surface or, if
endocytosed, are most likely trafficked through a degradation pathway to the lysosome.
For specifically targeting NPs to M cells, several targeting molecules have been tested,
including bacterial adhesins (82), peptides, IgA antibodies (83), and toxins (84). While
interactions with M cells may lead to enhanced uptake, there is the possible risk that
continuous absorption of NPs may induce an immune response (85).
Other NPs have targeted receptors that traffic through known transcytosis pathways. One
example is the transferrin receptor, which is involved in the transport of iron across cellular
barriers such as the epithelial barrier of the intestine (86). Studies with the transferrin
receptor have focused on protein-transferrin conjugates, while transferrin-NP conjugates
have not been studied significantly for oral delivery. The folate receptor has been studied
for folic acid transcytosis in the kidneys (87) and has been shown to enhance transport of
drugs across Caco-2 monolayers in vitro (88).
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Another transcytosis receptor studied for oral delivery is the vitamin B12 receptor. When
vitamin B12 is ingested, it is bound by intrinsic factor (IF) in the small intestine and the
vitamin B12-IF complex interacts with an IF receptor that traffics across the intestinal
epithelium. Studies using insulin-encapsulated NPs with vitamin B12 conjugated to the
surface have demonstrated enhanced absorption of the insulin after oral administration
(89-91). The drawbacks of using this receptor are that vitamin B12 absorption occurs in the
distal section of the ileum, meaning the NPs have to travel most of the small intestine prior
to absorption. The receptor also traffics through the lysosome as it crosses the cell (92).
This technology is being commercialized by Apollo Life Sciences for the oral delivery of
insulin using a sugar-based polymer coated with vitamin B12 molecules (93).
1.5.7. Summary of Oral Delivery Technologies
Many of the oral delivery technologies discussed have shown promising results, but most
are still limited by low bioavailability. In the case of insulin, most oral delivery systems
studied require doses of 10-100 U/kg to generate hypoglycemic responses in animal models
(37), compared with doses of only 0.5-1 U/kg used in the clinic to treat diabetic patients
(94). Previous studies have suggested that the long-term administration of such high doses
of insulin transcellularly may induce mitogenic changes in the GI epithelium, as insulin is
also a growth factor (95). Furthermore, very few of the strategies tested would enable the
transport of NPs across the epithelial barrier. Only targeting of trancytosis receptors could
potentially enable this, but the transport of NPs across the intestinal epithelial barrier has
yet to be conclusively demonstrated in these systems.
In summary, approaches such as permeation enhancers and mucoadhesive materials have
the advantage of utilizing most of the absorption area of the small intestine, but rely on
manipulating the integrity of the epithelium in order to increase absorption of drugs, which
could potentially have toxic side effects. On the other hand, NPs targeted to receptors on M
cells and enterocytes utilize natural pathways to cross the epithelium without affecting
epithelial integrity. However, in the case of M cells, there is limited area for absorption and
the M cells are closely associated with immune cells. Other receptors, such as the vitamin
B12 pathway, are also only present in specific sections of the intestine and traffic through
the lysosomes. Ideally, a technology that could utilize most of the absorption area of the
intestine while crossing the epithelium through a natural transcytosis pathway would
combine the advantages of these different approaches.
1.6. NEONATAL Fc RECEPTOR (FcRn)
IgG antibodies play an important role in protective immunity against a wide range of
pathogens and toxins. As part of this role, IgG is the only class of antibody known to be
transferred from mother to offspring to confer short-term passive immunity (96). In
addition, IgG along with other antibody classes (IgA, IgM) is secreted into mucosal surfaces
to provide defense against microorganisms (97, 98). In order to perform these roles, IgG
must be able to cross epithelial barriers.
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The neonatal Fc receptor (FcRn) is responsible for mediating IgG transport across epithelial
barriers (98, 99). It was discovered as the receptor in the neonatal intestine that transports
IgG in breast milk from mother to offspring (100). However, FcRn is expressed into
adulthood at levels similar to fetal expression (101), playing several important roles in
immune surveillance and adaptive immunity (102). These roles include bidirectional
transport of IgG across epithelial barriers, protection of IgG and albumin from catabolism
(103-106), and cross-presentation of antigens in macrophages and dendritic cells (105,
107).
In adults, FcRn is observed in the apical region of epithelial cells in the small intestine and
diffusely throughout the colon (108). FcRn is also expressed in the vascular endothelium,
blood-brain barrier, kidneys, liver, lungs, and throughout the hematopoietic system (109,
105, 107). In epithelial tissue, FcRn enables the transport of IgG in both apical-to-basolateral
and basolatera-to-apical directions and accounts for the high concentrations of IgG relative
to IgA and IgM in mucosal surfaces (98, 99, 101, 108). For example, FcRn in the intestinal
epithelium was able to transport IgG to the luminal surface to bind antigens, followed by
transporting the IgG-antigen complex back to the lamina propria for processing by antigen
presenting cells such as dendritic cells (98).
FcRn is a heterodimer with an MHC class I-like heavy chain associated with a 32-
microglobulin light chain (Figure 1.6) (110, 111). Unlike the MHC class I molecule, the
peptide-binding groove for the FcRn is occluded. The FcRn interacts with the CH2 -CH 3 hinge
region of the Fc portion in IgG antibodies. This interaction is strictly dependent on pH, with
the receptor binding IgG with high affinity at acidic pH (<6.5) but not at neutral pH (7.4)
(112). The pH dependence of the FcRn-IgG interaction is due to histidine residues in the
hinge region of IgG interacting with acidic residues on the FcRn (111, 113).
Crystallographic analysis of FcRn indicates a 2:1 FcRn:Fc stoichiometry for the interaction
(115). There are two possible structural conformations for the FcRn-Fc complex based on
crystallography (Figure 1.7) (116, 117). The first is the "standing up complex", where two
FcRn molecules each bind symmetrically to one Fc hinge region. The other is the "lying
down complex", where two FcRn molecules bind Fc asymmetrically.
Because binding of IgG by FcRn requires an acidic environment, interactions between IgG
and FcRn can either occur in the intestinal lumen (Figure 1.8) or in acidified endosomes
(Figure 1.9). In the duodenum section of the intestine, the lumen is acidic and may facilitate
binding and endocytosis of IgG by FcRn (118, 119). IgG is then trafficked through a
transcytosis pathway to the basolateral surface, where exocytosis results in exposure to a
neutral pH environment, resulting in ligand disassociation. In tissues where the pH is not
acidic, IgG uptake likely occurs by fluid-phase pinocytosis. Interactions between IgG and
FcRn in acidified endosomes then results in binding, preventing IgG from trafficking to
lysosomes for degradation. The FcRn-IgG complex can then either be recycled back to the
original membrane or trafficked across the cell and released. This allows the FcRn to
transport IgG across the placenta in humans (118, 119), traffic IgG to mucosal surfaces
(102), and play a role in IgG catabolism by rescuing IgG from degradation, which explains
the long blood circulation half-life of IgG (120). The bidirectional nature of FcRn trafficking
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and pH dependence of interaction with IgG provides the flexibility required for the multiple
roles FcRn plays in immune protection.
Recent studies using electron tomography to track nanogold-labeled Fc trafficking in
neonatal rat intestine demonstrated that FcRn is transported through a complex pathway
involving a network of entangled tubular and irregular vesicles in order to reach the
basolateral surface of the cell (121). Both endocytosis and exocytosis of FcRn are associated
with clathrin. Other studies have demonstrated that the cytoplasmic tail of FcRn is critical
for basolateral membrane targeting as well as endocytosis and transcytosis trafficking.
Removing the cytoplasmic tail or mutating the calmodulin binding site causes redistribution
of FcRn and reduces IgG transport (122, 123).
FcRn intracellular trafficking can also be influenced by IgG valency. In a study using dendritic
cells, immune complexes with multiple IgG antibodies bound to FcRn resulted in trafficking
through a degradation pathway to lysosomes, potentially to facilitate antigen processing
and presentation (105). However, monomeric IgG bound to FcRn was recycled back to the
cell surface. In another study, wild-type IgG with two FcRn-binding sites was more
frequently trafficked away from the lysosomes than IgG with a single FcRn-binding site
(124).
There have been many efforts to take advantage of FcRn for therapeutic applications. One
application is the use of IgG Fc fusion proteins to overcome cellular barriers. In non-human
primates and in human phase I clinical trials, IgG Fc fused with erythropoietin was measured
in the blood after pulmonary administration (125-127). Follicle-stimulating hormone fused
with IgG Fc reached circulation after oral administration in newborn rats and after
pulmonary administration in non-human primates (128). The other application is the use of
IgG Fc fusion proteins to increase the half-life of therapeutic proteins and reduce dosing
frequency. IgG Fc fused with recombinant factor VIII has demonstrated extended half-life in
mice and dogs and is currently in phase Ill human clinical trials for the treatment of
hemophilia (129).
1.7. THESIS GOALS
The overall goal of this thesis was to evaluate whether polymeric NPs targeted to FcRn could
utilize the FcRn transcytosis pathway to cross the intestinal epithelial barrier for oral
delivery applications. Harnessing FcRn for transepithelial transport offers several
advantages over other strategies used for oral delivery. Using a transcytosis pathway to
cross the epithelium leaves intact the integrity of the epithelial barrier, avoiding the
potential safety issues and adverse effects associated with manipulating the permeability of
the intestine for paracellular or transcellular transport. Because FcRn is expressed
throughout the intestine, it also provides a significant increase in absorption surface area
compared with only targeting a specific portion such as M cells in the Peyer's patches.
IgG Fc fusion proteins have already demonstrated success in enabling protein therapeutics
to overcome cellular barriers in the lungs and intestines. However, NPs offer several
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advantages over fusion proteins including (1) transport of many drug molecules with each
transcytosis event; (2) protection of drug molecules, particularly protein therapeutics,
through encapsulation; and (3) mitigation of the need for drug modifications that could also
affect drug pharmacokinetics.
Chapter 1 of this thesis has provided background on the challenges of oral delivery,
technologies that have been developed to try to overcome those challenges, and an
introduction to FcRn as a potential target for NP oral delivery. Chapter 2 describes the
efforts made to design and engineer biodegradable polymeric NPs capable of targeting the
FcRn. In chapter 3, the FcRn-targeted NPs were evaluated both in vitro and in vivo to
determine if the NPs were capable of transepithelial transport using the FcRn transcytosis
pathway. Chapter 4 describes the development of FcRn-targeted NPs capable of
encapsulating a model biologic (insulin) in bioactive form and the efficacy of the NP-based
therapeutic after oral administration in mouse models. Finally, chapter 5 focuses on
potential future work to improve the FcRn-targeted NPs for oral delivery and other potential
applications.
1.8. REFERENCES
1. S. Aggarwal, What's fueling the biotech engine-2010 to 2011, Nat. Biotechnol. 29, 1083-
1089 (2011).
2. A. Z. Wang, R. Langer, 0. C. Farokhzad, Nanoparticle Delivery of Cancer Drugs, Annu. Rev.
Med. 63, 185-198 (2012).
3. G. M. Lanza, P. M. Winter, S. D. Caruthers, M. S. Hughes, T. Cyrus, J. N. Marsh, A. M.
Neubauer, K. C. Partlow, S. A. Wickline, Nanomedicine opportunities for cardiovascular
disease with perfluorocarbon nanoparticles, Nanomedicine 1, 321-329 (2006).
4. S. Krol, R. Ellis-Behnke, P. Marchetti, Nanomedicine for treatment of diabetes in an aging
population: state-of-the-art and future developments, Maturitas 73 (1), 61-67 (2012).
5. J. Hrkach, D. Von Hoff, M. M. Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa,
M. Figueiredo, A. Horhota, S. Low, K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E.
Schnipper, J. J. Song, Y. H. Song, J. Summa, D. Tompsett, G. Troiano, T. Van Geen Hoven, J.
Wright, P. LoRusso, P. W. Kantoff, N. H. Bander, C. Sweeney, 0. C. Farokhzad, R. Langer, S.
Zale, Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel
Nanoparticle with a Differentiated Pharmacological Profile, Sci. Transl. Med. 4, 128ra39-
128ra39 (2012).
6. M. E. Davis, J. E. Zuckerman, C. H. J. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D.
Heidel, A. Ribas, Evidence of RNAi in humans from systemically administered siRNA via
targeted nanoparticles, Nature 464, 1067-1070 (2010).
22
7. N. A. Peppas, N. J. Kavimandan, Nanoscale analysis of protein and peptide absorption:
insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles, Eur. J.
Pharm. Sci. 29, 183-197 (2006).
8. G. Liu, E. Franssen, M. I. Fitch, E. Warner, Patient preferences for oral versus intravenous
palliative chemotherapy, J. Clin. Oncol. 15, 110-115 (1997).
9. M. M. Borner, P. Schoffski, R. de Wit, F. Caponigro, G. Comella, A. Sulkes, G. Greim, G. J.
Peters, K. van der Born, J. Wanders, R. F. de Boer, C. Martin, P. Fumoleau, Patient
preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil
and leucovorin: a randomised crossover trial in advanced colorectal cancer, Eur. J. Cancer
38, 349-358 (2002).
10. J. von Pawel, U. Gatzemeier, J. L. Pujol, L. Moreau, S. Bildat, M. Ranson, G. Richardson, C.
Steppert, A. Riviere, I. Camlett, S. Lane, G. Ross, Phase ii comparator study of oral versus
intravenous topotecan in patients with chemosensitive small-cell lung cancer, J. Clin. Oncol.
19, 1743-1749 (2001).
11. M. Findlay, G. Von Minckwitz, A. Wardley, Effective oral chemotherapy for breast
cancer: pillars of strength, Ann. Oncol. 19, 212-222 (2008).
12. P. Pfeiffer, J. P. Mortensen, B. Bjerregaard, L. Eckhoff, K. Schonnemann, E. Sandberg, K.
Aabo, A. Jakobsen, Patient preference for oral or intravenous chemotherapy: A randomised
cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with
colorectal cancer, Eur. J. Cancer 42, 2738-2743 (2006).
13. L. A. DiMeglio, M. Peacock, Two-Year Clinical Trial of Oral Alendronate Versus
Intravenous Pamidronate in Children With Osteogenesis Imperfecta, J. Bone and Miner. Res.
21, 132-140 (2006).
14. R. James, C. Blanco, C. Farina, Savings in staff time as a result of switching from de
Gramont to oral capecitabine for patients with advanced colorectal cancer, Eur. J. Cancer 1
(Suppl 5), S83 (Abstr 271) (2003).
15. S. De Portu, L. G. Mantovani, A. Ravaioli, E. Tamburini, R. Bollina, C. Cozzi, A. M.
Grimaldi, T. E. Testa, C. Bianchessi, G. Carten, Cost Analysis of Capecitabine vs 5-
Fluorouracil-Based Treatment for Metastatic Colorectal Cancer Patients, J. Chemother. 22,
125-128 (2010).
16. F. Jansman, M. Postma, D. van Hartskamp, P. Willemse, J. Brouwers, Cost-benefit
analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal
cancer in the Netherlands, Clin. Ther. 26, 579-589 (2004).
17. K. Yabroff, J. Warren, K. Knopf, W. Davis, M. Brown, Estimating Patient Time Costs
Associated with Colorectal Cancer Care, Med. Care 43, 640-648 (2005).
23
18. S. Ward, E. Kaltenthaler, J. Cowan, M. Marples, B. Orr, M. Seymour, The clinical and
economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer,
Br. J. Cancer 95, 27-34 (2006).
19. I. Kuppens, P. Breedveld, J. Schellens, Modulation of oral drug bioavailability: from
preclinical mechanism to therapeutic application, Cancer Invest. 23, 443-464 (2005).
20. C. Twelves, S. Gollins, R. Grieve, L. Samuel, A randomised cross-over trial comparing
patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients
with advanced colorectal cancer, Ann. Oncol. 17, 239-245 (2006).
21. G. Tortora, Principles of Human Anatomy (John Wiley & Sons, Inc., New York, 2005).
22. M. Schenk, C. Mueller, The mucosal immune system at the gastrointestinal barrier, Best
Pract. Res. Clin Gastrenterol. 22, 391-409 (2008).
23. T. Macdonald, G. Monteleone, Immunity, Inflammation, and Allergy in the Gut, Science
307, 1920-1925 (2005).
24. T. Kararli, Comparison of the gastrointestinal anatomy, physiology, and bio- chemistry of
humans and commonly used laboratory-animals, Biopharm. Drug Dispos. 16, 351-380
(1995).
25. A. Sood, R. Panchagnula, Peroral route: an opportunity for protein and peptide drug
delivery, Chem. Rev. 101, 3275-3304 (2001).
26. V. Ganapathy, N. Gupta, R. Martindale, Protein digestion and absorption. Physiology of
the gastrointestinal tract (Academic Press, Burlington, 4th ed., 2006).
27. L. Johnson, J. Christensen, M. Jackson, E. Jacobson, J. Walsh, Physiology of the
Gastrointestinal Tract (Raven Press, New York, 1987).
28. L. M. Ensign, R. Cone, J. Hanes, Oral drug delivery with polymeric nanoparticles: The
gastrointestinal mucus barriers, Adv. Drug Deliv. Rev. 64, 557-570 (2012).
29. C. Atuma, V. Strugala, A. Allen, L. Holm, The adherent gastrointestinal mucus gel layer:
thickness and physical state in vivo, Am. J. Physiol. Gastrointest. Liver Physiol. 280, G922-
G929 (2001).
30. S. K. Lai, Y.-Y. Wang, D. Wirtz, J. Hanes, Micro-and macrorheology of mucus, Adv. Drug
Deliv. Rev. 61, 86-100 (2009).
31. R. A. Cone, Barrier properties of mucus, Adv. Drug Deliv. Rev. 61, 75-85 (2009).
32. L. L. Mitic, C. M. Van Itallie, J. M. Anderson, Molecular physiology and pathophysiology
of tight junctions I. Tight junction structure and function: lessons from mutant animals and
proteins, Am. J. Physiol. Gastrointest. Liver Physiol. 279, G250-G254 (2000).
24
33. M. D. DeMario, M. J. Ratain, Oral chemotherapy: rationale and future directions, J. Clin.
Oncol. 16, 2557-2567 (1998).
34. A. Hayday, E. Theodoridis, E. Ramsburg, J. Shires, Intraepithelial lymphocytes: exploring
the Third Way in immunology, Nat. Immunol. 2, 997-1003 (2001).
35. H. Cheroutre, Starting at the beginning: new perspectives on the biology of mucosal T
cells, Annu. Rev. Immunol. 22, 217-246 (2004).
36. B. L. Kelsall, W. Strober, in Springer Seminars in Immunopathology, (1997), vol. 18, pp.
409-420.
37. M.-C. Chen, K. Sonaje, K.-J. Chen, H.-W. Sung, A review of the prospects for polymeric
nanoparticle platforms in oral insulin delivery, Biomaterials 32, 9826-9838 (2011).
38. N. Salama, N. Eddington, A. Fasano, Tight junction modulation and its relationship to
drug delivery, Adv. Drug Deliv. Rev. 58, 15-28 (2006).
39. M. Morishita, I. Morishita, K. Takayama, Y. Machida, T. Nagai, Site-dependent effect of
aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of
insulin, Biol Pharm Bull. 16, 68-72 (1993).
40. A. Bernkop-SchnOrch, The use of inhibitory agents to overcome the enzymatic barrier to
perorally administered therapeutic peptides and proteins, J. Control Release 52, 1-16
(1998).
41. J. E. Reseland, H. Holm, M. B. Jacobsen, T. G. Jenssen, L. E. Hanssen, Proteinase
inhibitors induce selective stimulation of human trypsin and chymotrypsin secretion, J. Nutr.
126, 634-642 (1996).
42. K. Whitehead, Z. Shen, S. Mitragotri, Oral delivery of macromolecules using intestinal
patches: applications for insulin delivery, J. Control Release 98, 37-45 (2004).
43. K. S. Kan, R. Coleman, The calcium ionophore A23187 increases the tight-junctional
permeability in rat liver, Biochem. J. 256, 1039 (1988).
44. A. Fasano, S. Uzzau, Modulation of intestinal tight junctions by Zonula occludens toxin
permits enteral administration of insulin and other macromolecules in an animal model, J.
Clin. Invest. 99, 1158 (1997).
45. T.-H. Yeh, L.-W. Hsu, M. T. Tseng, P.-L. Lee, K. Sonjae, Y.-C. Ho, H.-W. Sung, Mechanism
and consequence of chitosan-mediated reversible epithelial tight junction opening,
Biomaterials 32, 6164-6173 (2011).
46. S.-J. Wu, J. R. Robinson, Transport of human growth hormone across Caco-2 cells with
novel delivery agents: evidence for P-glycoprotein involvement, J. Control Release 62, 171-
177 (1999).
25
47. G. M. Mlynek, L. J. Calvo, J. R. Robinson, Carrier-enhanced human growth hormone
absorption across isolated rabbit intestinal tissue, Int. J. Pharm. 197, 13-21 (2000).
48. K. Park, I. C. Kwon, K. Park, Oral protein delivery: current status and future prospect,
Reactive and Functional Polymers 71, 280-287 (2011).
49. S. Galindo-Rodriguez, E. Allemann, H. Fessi, E. Doelker, Polymeric nanoparticles for oral
delivery of drugs and vaccines: a critical evaluation of in vivo studies, Crit. Rev. Ther. Drug
Carrier Syst. 22, 419-464 (2005).
50. Carino, Mathiowitz, Oral insulin delivery, Adv. Drug Deliv. Rev. 35, 249-257 (1999).
51. P. J. Lowe, C. S. Temple, Calcitonin and insulin in isobutylcyanoacrylate nanocap- sules -
protection against proteases and effect on intestinal-absorption in rats, J. Pharm.
Pharmacol. 46, 547-552. (1994).
52. C. Damge, H. Vranckx, P. Balschmidt, P. Couvreur, Poly (alkyl cyanoacrylate)
nanospheres for oral administration of insulin, J. Pharm. Sci. 86, 1403-1409 (1997).
53. H. M. Mansour, Y.-S. Rhee,, X. Wu,, Nanomedicine in pulmonary delivery, Int. J.
Nanomed. 4, 299-319 (2009).
54. J. Smart, The basics and underlying mechanisms of mucoadhesion, Adv. Drug Deliv. Rev.
57, 1556-1568 (2005).
55. A. des Rieux, V. Fievez, M. Garinot, Y.-J. Schneider, V. Preat, Nanoparticles as potential
oral delivery systems of proteins and vaccines: a mechanistic approach, J. Control Release
116, 1-27 (2006).
56. S. K. Lai, Y.-Y. Wang, J. Hanes, Mucus-penetrating nanoparticles for drug and gene
delivery to mucosal tissues, Adv. Drug Deliv. Rev. 61, 158-171 (2009).
57. S. Dunnhaupt, J. Barthelmes, J. Hombach, D. Sakloetsakun, V. Arkhipova, A. Bernkop-
Schnirch, Distribution of thiolated mucoadhesive nanoparticles on intestinal mucosa, Int. J.
Pharm. 408, 191-199 (2011).
58. A. Makhlof, M. Werle, Y. Tozuka, H. Takeuchi, A mucoadhesive nanoparticulate system
for the simultaneous delivery of macromolecules and permeation enhancers to the
intestinal mucosa, J. Control Release 149, 81-88 (2011).
59. Y. Qiu, K. Park, Environment-sensitive hydrogels for drug delivery, Adv. Drug Deliv. Rev.
53, 321-339 (2001).
60. F. Madsen, N. A. Peppas, Complexation graft copolymer networks: swelling properties,
calcium binding and proteolytic enzyme inhibition, Biomaterials 20, 1701-1708 (1999).
26
61. M. Torres-Lugo, M. Garcia, R. Record, N. A. Peppas, Physicochemical behavior and
cytotoxic effects of p (methacrylic acid-g-ethylene glycol) nanospheres for oral delivery of
proteins, J. Control Release 80, 197-205 (2002).
62. T. Morcol, P. Nagappan, L. Nerenbaum, A. Mitchell, S. J. D. Bell,, Calcium phosphate-
PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin, Int. J. Pharmaceut.
277, 91-97 (2004).
63. M. P. Desai, V. Labhasetwar, G. L. Amidon, R. J. Levy, Gastrointestinal uptake of
biodegradable microparticles: effect of particle size, Pharm. Res. 13, 1838-1845 (1996).
64. P. Jani, G. W. Halbert, J. Langridge, A. T. Florence, Nanoparticle uptake by the rat
gastrointestinal mucosa: quantitation and particle size dependency, J. Pharm. Pharmacol. 42
(12), 821-826 (1990).
65. I. Behrens, A. I. Pena, M. J. Alonso, T. Kissel, Comparative uptake studies of bioadhesive
and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of
mucus on particle adsorption and transport, Pharm Res. 19, 1185-93 (2002).
66. H. Hillaireau, P. Couvreur, Nanocarriers' entry into the cell: relevance to drug delivery,
Cell Mol. Life Sci. 66, 2873-2896 (2009).
67. M. H. Jang, M.-N. Kweon, K. Iwatani, M. Yamamoto, K. Terahara, C. Sasakawa, T. Suzuki,
T. Nochi, Y. Yokota, P. D. Rennert, Intestinal villous M cells: an antigen entry site in the
mucosal epithelium, Proc. Natl. Acad. Sci. USA 101, 6110-6115 (2004).
68. 0. Kammona, C. Kiparissides, Recent advances in nanocarrier-based mucosal delivery of
biomolecules, J. Control Release 161 (3), 781-794 (2012).
69. A. des Rieux, V. Fievez, I. Theate, J. Mast, V. Pr6at, Y.-J. Schneider, An improved in vitro
model of human intestinal follicle-associated epithelium to study nanoparticle transport by
M cells, Eur. J. Pharm. Sci. 30, 380-391 (2007).
70. E. Roger, F. Lagarce, E. Garcion, J.-P. Benoit, Biopharmaceutical parameters to consider
in order to alter the fate of nanocarriers after oral delivery, Nanomedicine 5, 287-306
(2010).
71. B. Slktter, N. Hagenaars, W. Jiskoot, Rational design of nasal vaccines, J. Drug Target. 16,
1-17 (2008).
72. B. C. Tang, M. Dawson, S. K. Lai, Y.-Y. Wang, J. S. Suk, M. Yang, P. Zeitlin, M. P. Boyle, J.
Fu, J. Hanes, Biodegradable polymer nanoparticles that rapidly penetrate the human mucus
barrier, Proc. Natl. Acad. Sci. USA 106, 19268-19273 (2009).
73. J. H. Eldridge, C. J. Hammond, J. A. Meulbroek, J. K. Staas, R. M. Gilley, T. R. Tice,
Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered
27
biodegradable microspheres target the Peyer's patches, J. Control Release 11, 205-214
(1990).
74. F. Gabor, A. Schwarzbauer, M. Wirth, Lectin-mediated drug delivery: binding and uptake
of BSA-WGA conjugates using the Caco-2 model, Int. J. Pharm. 237, 227-239 (2002).
75. F. Gabor, M. Wirth, B. Jurkovich, I. Haberl, G. Theyer, G. Walcher, G. Hamilton, Lectin-
mediated bioadhesion: Proteolytic stability and binding-characteristics of wheat germ
agglutinin and Solanum tuberosum lectin on Caco-2, HT-29 and human colonocytes, J.
Control Release 49, 27-37 (1997).
76. M. Clark, B. H. Hirst, M. A. Jepson, Lectin-mediated mucosal delivery of drugs and
microparticles, Adv. Drug Deliv. Rev. 43, 207-223 (2000).
77. J. M. Irache, C. Durrer, D. Duchene, G. Ponchel, Preparation and characterization of
lectin-latex conjugates for specific bioadhesion, Biomaterials 15, 899-904 (1994).
78. D. C. Kilpatrick, A. Pusztai, G. Grant, C. Graham, S. W. Ewen, Tomato lectin resists
digestion in the mammalian alimentary canal and binds to intestinal villi without deleterious
effects, FEBS Lett. 185, 299-305 (1985).
79. N. Hussain, P. U. Jani, A. T. Florence, Enhanced oral uptake of tomato lectin- conjugated
nanoparticles in the rat, Pharm. Res. 14, 613-618 (1997).
80. A. Weissenboeck, E. Bogner, M. Wirth, F. Gabor, Binding and uptake of wheat germ
agglutinin-grafted PLGA-nanospheres by caco-2 monolayers, Pharm. Res. 21, 1917-1923
(2004).
81. N. Lochner, F. Pittner, M. Wirth, F. Gabor, Wheat germ agglutinin binds to the epidermal
growth factor receptor of artificial Caco-2 membranes as detected by silver nanoparticle
enhanced fluorescence, Pharm. Res. 20, 833-839 (2003).
82. M. Clark, M. A. Jepson, B. H. Hirst, Exploiting M cells for drug and vaccine delivery, Adv.
Drug Deliv. Rev. 50, 81-106 (2001).
83. C. Porta, P. S. James, A. D. Phillips, T. C. Savidge, M. W. Smith, D. Cremaschi, Confocal
analysis of fluorescent bead uptake by mouse Peyer's patch follicle-associated M cells, Exp.
Physiol. 77, 929-932 (1992).
84. D. J. Brayden, Oral vaccination in man using antigens in particles: current status, Eur. J.
Pharm. Sci. 14, 183-189 (2001).
85. E.-S. Khafagy, M. Morishita, Y. Onuki, K. Takayama, Current challenges in non-invasive
insulin delivery systems: a comparative review, Adv. Drug Deliv. Rev. 59, 1521-1546 (2007).
86. C. Q. Xia, J. Wang, W.-C. Shen, Hypoglycemic effect of insulin-transferrin conjugate in
streptozotocin-induced diabetic rats, J. Pharmacol. Exp. Ther. 295, 594-600 (2000).
28
87. R. M. Sandoval, M. D. Kennedy, P. S. Low, B. A. Molitoris, Uptake and trafficking of
fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon
microscopy, Am. J. Physiol. Cell Physiol. 287, C517-C526 (2004).
88. E. Roger, S. Kalscheuer, A. Kirtane, B. R. Guru, A. E. Grill, J. Whittum-Hudson, J. Panyam,
Folic Acid Functionalized Nanoparticles for Enhanced Oral Drug Delivery, Mol. Pharm. 9,
2103-2110 (2012).
89. K. B. Chalasani, G. J. Russell-Jones, A. K. Jain, P. V. Diwan, S. K. Jain, Effective oral delivery
of insulin in animal models using vitamin B12-coated dextran nanoparticles, J. Control
Release 122, 141-150 (2007).
90. K. B. Chalasani, G. J. Russell-Jones, S. K. Yandrapu, P. V. Diwan, S. K. Jain, A novel vitamin
B12-nanosphere conjugate carrier system for peroral delivery of insulin, J. Control Release
117, 421-429 (2007).
91. A. K. Petrus, T. J. Fairchild, R. P. Doyle, Traveling the Vitamin B12 Pathway: Oral Delivery
of Protein and Peptide Drugs, Angew. Chem. Int. Ed. 48, 1022-1028 (2009).
92. W. J. Jenkins, R. Empson, D. P. Jewell, K. B. Taylor, Subcellular localisation of vitamin B12
during absorption in the guinea-pig ileum, Gut 22, 617-622 (1981).
93. J. Alsenz, G. J. Russell-Jones, S. Westwood, B. Levet-Trafit, P. C. de Smidt, Oral
absorption of peptides through the cobalamin (vitamin B12) pathway in the rat intestine,
Pharm. Res. 17, 825-832 (2000).
94. E. Cochran, C. Musso, P. Gorden, The use of U-500 in patients with extreme insulin
resistance, Diabetes Care 28, 1240-1244 (2005).
95. R. N. Brogden, R. C. Heel, Human insulin. A review of its biological activity,
pharmacokinetics and therapeutic use, Drugs 34, 350-371 (1987).
96. L. G. Morphis, D. Gitlin, Maturation of the maternofoetal transport system for human
gamma-globulin in the mouse, Nature. 228 (5271), 573 (1970).
97. M. Robert-Guroff, IgG surfaces as an important component in mucosal protection, Nat.
Med. 6, 129-130 (2000).
98. M. Yoshida, S. M. Claypool, J. S. Wagner, E. Mizoguchi, A. Mizoguchi, D. C. Roopenian,
W. I. Lencer, R. S. Blumberg, Human neonatal Fc receptor mediates transport of IgG into
luminal secretions for delivery of antigens to mucosal dendritic cells, Immunity 20, 769-783
(2004).
99. B. L. Dickinson, K. Badizadegan, Z. Wu, J. C. Ahouse, X. Zhu, N. E. Simister, R. S.
Blumberg, W. I. Lencer, Bidirectional FcRn-dependent IgG transport in a polarized human
intestinal epithelial cell line, J. Clin. Invest. 104, 903-911 (1999).
29
100. F. W. Brambell, The transmission of immune globulins from the mother to the foetal
and newborn young, Proc. Nutr. Soc. 28, 35-41 (1969).
101. U. Shah, B. L. Dickinson, R. S. Blumberg, N. E. Simister, W. 1. Lencer, W. A. Walker,
Distribution of the IgG Fc receptor, FcRn, in the human fetal intestine, Pediatr. Res. 53, 295-
301 (2003).
102. M. Yoshida, K. Kobayashi, T. T. Kuo, L. Bry, J. N. Glickman, S. M. Claypool, A. Kaser, T.
Nagaishi, D. E. Higgins, E. Mizoguchi, Y. Wakatsuki, D. C. Roopenian, A. Mizoguchi, W. 1.
Lencer, R. S. Blumberg, Neonatal Fc receptor for IgG regulates mucosal immune responses
to luminal bacteria, J. Clin. Invest. 116, 2142-2151 (2006).
103. R. P. Junghans, C. L. Anderson, The protection receptor for IgG catabolism is the beta2-
microglobulin-containing neonatal intestinal transport receptor, Proc. Nat. Acad. Sci. USA
93, 5512-5516 (1996).
104. R. J. Ober, C. Martinez, C. Vaccaro, J. Zhou, E. S. Ward, Visualizing the site and dynamics
of IgG salvage by the MHC class I-related receptor, FcRn, J. Immunol. 172, 2021-2029
(2004).
105. S. W. Qiao, K. Kobayashi, F. E. Johansen, L. M. Sollid, J. T. Andersen, E. Milford, D. C.
Roopenian, W. 1. Lencer, R. S. Blumberg, Dependence of antibody-mediated presentation of
antigen on FcRn, Proc. Natl. Acad. Sci. USA 105, 9337 (2008).
106. S. Tzaban, R. H. Massol, E. Yen, W. Hamman, S. R. Frank, L. A. Lapierre, S. H. Hansen, J.
R. Goldenring, R. S. Blumberg, W. 1. Lencer, The recycling and transcytotic pathways for IgG
transport by FcRn are distinct and display an inherent polarity, J. Cell Biol. 185, 673-684
(2009).
107. K. Baker, S.-W. Qiao, T. T. Kuo, V. G. Aveson, B. Platzer, J.-T. Andersen, I. Sandlie, Z.
Chen, C. de Haar, W. 1. Lencer, E. Fiebiger, R. S. Blumberg, Neonatal Fc receptor for IgG
(FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic
cells, Proc. Natl. Acad. Sci. USA 108, 9927-9932 (2011).
108. E. J. Israel, S. Taylor, Z. Wu, E. Mizoguchi, R. S. Blumberg, A. Bhan, N. E. Simister,
Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells,
Immunology 92, 69-74 (1997).
109. T. T. Kuo, V. G. Aveson, Neonatal Fc receptor and IgG-based therapeutics, MAbs 3,
422-430 (2011).
110. N. E. Simister, K. E. Mostov, An Fc receptor structurally related to MHC class I antigens,
Nature 337, 184-187 (1989).
111. M. Raghavan, L. N. Gastinel, P. J. Bjorkman, The class I major histocompatibility
complex related Fc receptor shows pH-dependent stability differences correlating with
immunoglobulin binding and release, Biochemistry 32, 8654-8660 (1993).
30
112. R. Rodewald, pH-dependent binding of immunoglobulins to intestinal cells of the
neonatal rat, J. Cell Biol. 71, 666-669 (1976).
113. R. L. Shields, A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae, J. Briggs, D. Xiei, J. Lai, A.
Stadlen, B. Li, J. A. Fox, L. G. Presta, High Resolution Mapping of the Binding Site on Human
IgG1 for FcgRI, FcgRIl, FcgRlll, and FcRn and Design of IgG1 Variants with Improved Binding
to the FcgR, J. Biol. Chem. 276, 6591-6604 (2001).
114. D. C. Roopenian, S. Akilesh, FcRn: the neonatal Fc receptor comes of age, Nat. Rev.
Immunol. 7, 715-725 (2007).
115. A. H. Huber, R. F. Kelley, L. N. Gastinel, P. J. Bjorkman, Crystallization and stoichiometry
of binding of a complex between a rat intestinal Fc receptor and Fc, J. Mol. Biol. 230, 1077-
1083 (1993).
116. W. P. Burmeister, A. H. Huber, P. J. Bjorkman, Crystal structure of the complex of rat
neonatal Fc receptor with Fc, Nature 372, 379-383 (1994).
117. A. R. Mezo, V. Sridhar, J. Badger, P. Sakorafas, V. Nienaber, X-ray crystal structures of
monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor,
FcRn, J. Biol. Chem. 285, 27694-27701 (2010).
118. D. Lalezari, Gastrointestinal pH profile in subjects with irritable bowel syndrome,
Annals of Gastroenterology 25, 333 (2012).
119. T. T. Kuo, K. Baker, M. Yoshida, S.-W. Qiao, V. G. Aveson, W. I. Lencer, R. S. Blumberg,
Neonatal Fc Receptor: From Immunity to Therapeutics, J. Clin. Immunol. 30, 777-789
(2010).
120. E. S. Ward, J. Zhou, V. Ghetie, R. J. Ober, Evidence to support the cellular mechanism
involved in serum IgG homeostasis in humans, Int. Immunol. 15, 187-195 (2003).
121. W. He, M. S. Ladinsky, K. E. Huey-Tubman, G. J. Jensen, J. R. McIntosh, P. J. Bj6rkman,
FcRn-mediated antibody transport across epithelial cells revealed by electron tomography,
Nature 455, 542-546 (2008).
122. S. M. Claypool, B. L. Dickinson, J. S. Wagner, F.-E. Johansen, N. Venu, J. A. Borawski, W.
I. Lencer, R. S. Blumberg, Bidirectional transepithelial IgG transport by a strongly polarized
basolateral membrane Fcy-receptor, Mol. Biol. Cell 15, 1746-1759 (2004).
123. B. L. Dickinson, S. M. Claypool, J. A. D'Angelo, M. L. Aiken, N. Venu, E. H. Yen, J. S.
Wagner, J. A. Borawski, A. T. Pierce, R. Hershberg, Ca2+-dependent calmodulin binding to
FcRn affects immunoglobulin G transport in the transcytotic pathway, Mol. Biol. Cell 19,
414-423 (2008).
31
124. D. B. Tesar, N. E. Tiangco, P. J. Bjorkman, Ligand valency affects transcytosis, recycling
and intracellular trafficking mediated by the neonatal Fc receptor, Traffic 7, 1127-1142
(2006).
125. A. J. Bitonti, J. A. Dumont, S. C. Low, R. T. Peters, K. E. Kropp, V. J. Palombella, J. M.
Stattel, Y. Lu, C. A. Tan, J. J. Song, others, Pulmonary delivery of an erythropoietin Fc fusion
protein in non-human primates through an immunoglobulin transport pathway, Proc. Nat!.
Acad. Sci. USA 101, 9763 (2004).
126. A. J. Bitonti, J. A. Dumont, Pulmonary administration of therapeutic proteins using an
immunoglobulin transport pathway, Adv. Drug Deliv. Rev. 58, 1106-1118 (2006).
127. J. A. Dumont, A. J. Bitonti, D. Clark, S. Evans, M. Pickford, Delivery of an Erythropoietin-
Fc Fusion Protein by Inhalation in Humans through an Immunoglobulin Transport Pathway,
J. Aerosol Med. 18, 294-303 (2005).
128. S. C. Low, Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc
receptor-mediated transcytosis, Hum. Reprod. 20, 1805-1813 (2005).
129. J. A. Dumont, T. Liu, S. C. Low, X. Zhang, G. Kamphaus, P. Sakorafas, C. Fraley, D.
Drager, T. Reidy, J. McCue, Prolonged activity of a recombinant factor VIII-Fc fusion protein
in hemophilia A mice and dogs, Blood 119, 3024-3030 (2012).
32
Vein carrying blood
to hepatic portal
vessel
Vill
Intestinal wall
Microvilli
(brush border)
Epfthellal cells
-Lymph
vessel
Figure 1.1. Major GI tract components for digestion and absorption. The stomach and
small intestine are the major sites of digestion. The small intestine is also responsible for
absorption of nutrients, with the surface area increased by microscopic finger-like
projections called villi. The epithelial barrier between the intestinal lumen and lamina
propria consists of a monolayer of cells that tightly regulates transepithelial transport (21).
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Figure 1.2. Schematic representation of the intestinal villi and cell types. The cell types
present in the villi include absorptive enterocyte cells, goblet cells, endocrine cells, and
Paneth cells (21).
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Figure 1.3. Schematic of the mucus layer thickness throughout the GI tract. The mucus
barrier consists of a loosely adherent layer and a firmly adherent layer that vary in thickness
throughout the GI tract (29).
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Figure 1.4. Pathways for intestinal transepithelial transport. The transport pathways
include paracellular, transcellular, and transcytosis pathways.
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Figure 1.5. Schematic of M cells and underlying immune cells. M cells are associated with
Peyer's Patches, which are organized components of the gut-associated lymphoid tissue
(GALT). M cells transport antigens through a non-degradative pathway across the
epithelium to underlying antigen presenting cells such as dendritic cells. M cells lack
microvilli, do not secrete mucus or digestive enzymes, and have a thinner glycocalyx,
allowing for easier access to antigens in the intestinal lumen.
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Figure 1.6. Structure of the FcRn associated with the Fc region of an IgG antibody. FcRn is a
heterodimer with an MHC class I-like heavy chain associated with a @2-microglobulin light
chain. The FcRn interacts with the CH2-CH3 hinge region of the Fc portion in IgG antibodies
(114).
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Figure 1.7. Possible structural conformations for the FcRn-Fc complex. The Fc portion of
IgG is represented in red, the MHC class I-like chain of FcRn in blue, and the P2-
microglobulin chain of FcRn in green (116).
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Figure 1.8. FcRn trafficking of IgG with an acidic apical surface. IgG is bound and
endocytosed by FcRn at the cell surface under acidic conditions. IgG remains bound to FcRn
in acidic endosomes as it is trafficked across the cell through a transcytosis pathway. On the
basolateral side during exocytosis, IgG dissociates from FcRn under neutral conditions.
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Figure 1.9. FcRn trafficking of IgG with a neutral apical surface. IgG is taken up by fluid-
phase pinocytosis and binds to FcRn once in acidic endosomes. The FcRn:IgG complex can
then be trafficked through a transcytosis or recycling pathway. During exocytosis at either
the apical or basolateral side, IgG dissociates from FcRn under neutral conditions.
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Chapter 2. Engineering of Neonatal Fc Receptor-Targeted Nanoparticles
2.1. ABSTRACT
Polymeric nanoparticles (NPs) offer a high degree of flexibility for engineering a drug
delivery system. In this chapter, polymers were used to develop NPs targeted to the
neonatal Fc receptor (FcRn). The FcRn-targeted NPs were developed using the
biodegradable and biocompatible polymers poly(lactic acid) (PLA), poly(ethylene glycol)
(PEG), and poly(lactic-co-glycolic acid) (PLGA). The NPs were engineered to have a particle
size of less than 100 nanometers (nm) and IgG Fc fragments conjugated to the NP surface to
target the FcRn. The NPs were formed using the nanoprecipitation self-assembly method.
Several formulation parameters were evaluated for their effects on NP size. The results
showed that lower polymer concentrations, lower PLA molecular weights, and optimized
solvent:water volume ratios resulted in NPs with a size of 50-60 nm. The IgG Fc was
covalently conjugated to the NP surface using thiol-maleimide chemistry. Several different
conjugation reaction parameters were investigated, such as the ratio of 2-iminothiolane to
IgG Fc, addition of ethylenediaminetetraacetic acid (EDTA), and reaction time and
temperature, to ensure efficient IgG Fc conjugation to the NP surface while minimizing
payload release. Control over the amount of IgG Fc on the NP surface was also
demonstrated. Finally, non-targeted NP and FcRn-targeted NP (NP-Fc) particle stability was
investigated by studying changes in particle size under stomach and duodenum pH
conditions. No significant particle aggregation was observed over timescales relevant for
oral delivery applications. Based on these studies, NPs were developed that met the design
criteria of being biodegradable and biocompatible, less than 100 nm in diameter, surface-
modified with IgG Fc for FcRn targeting, and stable in low pH environments similar to those
encountered in the gastrointestinal (GI) tract.
2.2. INTRODUCTION
NPs are being developed to treat many different diseases, including cancer (1),
cardiovascular disease (2), and diabetes (3). One significant advantage of using polymeric
NPs is the flexibility provided to engineer specific physicochemical properties into the drug
delivery system (4). NP delivery systems consist of several components that can be
engineered based on the desired application. These components are the core, corona,
targeting ligand, and payload (Figure 2.1). Considerations of each component are necessary
when designing a delivery system because each component affects the overall performance
of the system (5). The core region affects drug encapsulation and release profiles (6). The
corona region influences the particle surface charge, stability, and pharmacokinetics (7).
Targeting ligands are used to influence cell binding and uptake as well as tissue
biodistribution (8). The payload used is dependent on the application, but could consist of
therapeutic or imaging agents.
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The aim of these studies was to develop NPs targeted to the FcRn for oral delivery
applications. The NPs were composed of biodegradable or biocompatible materials
currently approved by the Food and Drug Administration (FDA) for clinical use. This would
ensure that the materials were safe for use in humans and facilitate potential translation
into clinical use. Therefore, the core of the NPs was composed of poly(lactic acid) (PLA)
because it has been used in the clinic as a biomaterial in Vicryl sutures and as an excipient
for sustained release of parenteral drugs (9, 10). PLA is biodegradable, hydrolyzing into
lactic acid over time (11). The corona was composed of polyethylene glycol (PEG), which is a
biocompatible material. PEG has been demonstrated to improve NP stability through steric
repulsion and electrostatic interactions depending on the terminal group of the PEG, which
influences the surface charge of the NPs (12, 13). PEG also minimizes opsonization of
proteins on the NP surface, reducing phagocytic uptake and increasing the blood circulation
half-life of the NPs (14-16). Finally, high densities of PEG on NP surfaces have been shown
to increase the diffusion rate of NPs through mucus barriers (17-19). This could be
advantageous for oral delivery applications since a mucus layer covers the intestinal
epithelium. The targeting ligand is the Fc fragment of IgG (20), which binds to the FcRn and
should facilitate NP transport through the FcRn transcytosis pathway. Finally, the payload
could be a number of different molecules depending on the application. For example,
fluorescent dyes could be conjugated to PLA and encapsulated for in vitro or in vivo imaging
(21, 22). Radioactive molecules could be conjugated to PLA as well for tracking and
quantification of NP transport both in vitro and in vivo (23). In addition, therapeutic agents
such as drugs or biologic molecules could be encapsulated in the NP core for in vivo efficacy
studies.
There are several different self-assembly techniques that are used to form NPs from
polymers (Figure 2.2). For hydrophilic drugs and biologic molecules such as insulin, the
double emulsion technique is typically used because the molecules being encapsulated are
dissolved in an aqueous solution prior to encapsulation (24). In this technique, the drug is
dissolved in the aqueous phase and emulsified with a surfactant in a water-immiscible
organic solvent containing the polymer. This first emulsion is then added to a second
aqueous phase with or without surfactant to form the second emulsion, where polymer
precipitation into NPs occurs due to solvent evaporation. The double emulsion technique
typically yields NPs with sizes over 100 nm, usually 150-250 nm (25, 26).
Another technique used to form NPs from polymers is the nanoprecipitation method. This
method is usually used to encapsulate lipophilic drugs. The nanoprecipitation method
requires the drug to be soluble in a water-miscible organic solvent. NPs are formed
instantaneously upon addition of the organic phase to the aqueous phase due to rapid
solvent displacement, resulting in a reduced particle size without the need for sonication or
homogenization (27). Using the nanoprecipitation method, particle sizes less than 100 nm
are achievable (6, 28).
In this chapter, a NP delivery system was developed using the biodegradable and
biocompatible diblock copolymer PLA-PEG. The copolymer was synthesized using ring
opening polymerization. NPs were formed from PLA-PEG using the nanoprecipitation self-
assembly method, and several formulation parameters were studied to achieve a target NP
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size of less than 100 nm. The IgG Fc was covalently conjugated to the NP surface using thiol-
maleimide chemistry, with several conjugation parameters investigated to optimize the
reaction. Finally, the stability of the non-targeted and targeted NPs were studied in
solutions mimicking the pH environments of the stomach and duodenum to demonstrate
that there was no aggregation of the NPs over timescales relevant to oral delivery
applications.
2.3. MATERIALS AND METHODS
2.3.1. Materials
D,L-lactide was from Sigma-Aldrich. Poly(lactic-co-glycolic acid) (PLGA) with 50:50 G:L ratio
and terminal carboxylate groups (inherent viscosity 0.20 dL/g, molecular weight (MW) -5
kDa) was from Lactel. Maleimide PEG hydroxyl (MAL-PEG-OH, MW 3400) was from JenKem
Technology. Purified human polyclonal IgG Fc fragment prepared by papain digestion was
from Bethyl Laboratories. Dimethyl sulfoxide (DMSO), acetonitrile, and tin(ll) 2-
ethylhexanoate were from Sigma-Aldrich.
2.3.2. Synthesis of PLA-PEG
D,L-lactide and MAL-PEG-OH were used to synthesize PLA-PEG-MAL by ring opening
polymerization- D,L-lactide (3 g, 20.8 mmol) and MAL-PEG-OH (544 mg, 0.16 mmol) were
dissolved in 15 mL anhydrous toluene in a round bottom flask. Tin(II) ethylhexanoate (38
mg, 0.09 mmol) was then added. The flask with condenser was placed in an oil bath, purged
with nitrogen for 10 minutes, heated to 1200C, and reacted overnight while 4'C water
circulated through the condenser. Toluene was then evaporated and the polymer
precipitated in a mixture of ice-cold methanol and diethyl ether and vacuum-dried. The PLA-
PEG-MAL chemical structure was characterized by 1H NMR (400 MHz) and the molecular
weight was measured by gel permeation chromatography (GPC) using tetrahydrofuran (THF)
as the mobile phase and polystyrene standards.
2.3.3. NP Size Studies
The nanoprecipitation method was used for the formation of NPs from PLA-PEG and PLGA.
In general, the polymers were dissolved in organic solvents that are miscible in water. NPs
were formed by adding the polymer solution dropwise to water and allowing the mixture to
stir for 2 hr at room temperature. The resulting NPs were purified by filtration using
Millipore Amicon Ultra 100,000 NMWL membranes and washed with water or phosphate-
buffered saline (PBS). Formulation parameters were varied to study the effects on NP size.
The solvents evaluated were acetonitrile and dimethyl sulfoxide (DMSO). The polymer
molecular weight was studied by generating NPs with 13 kDa and 35 kDa PLA-PEG using a
polymer concentration of 10 mg/mL and a DMSO:water volume ratio of 1:4. The polymer
concentration was studied by preparing PLA-PEG in DMSO at concentrations ranging from 1
to 50 mg/mL prior to the dropwise addition to water (DMSO:water volume ratio = 1:5). The
DMSO:water volume ratio was investigated by varying the ratio from 1:11 to 1:1 with the
PLA-PEG concentration fixed at 50 mg/mL in DMSO. To study the effects of PLGA blending,
PLGA was blended with PLA-PEG in DMSO from 0-50% by weight at a polymer concentration
of 10 mg/mL and used to form NPs (DMSO:water volume ratio = 1:4). Finally, to remove
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aggregates after washing with the Millipore Amicon filters, the NPs were syringe-filtered
through 0.1 [tm Millipore filters. For each condition, after the NPs were formed and washed,
the particle size distribution was measured using dynamic light scattering with a
Brookhaven Instruments ZetaPALS at a temperature of 250C and a scattering angle of 90
with a NP concentration of 0.1 mg/mL in water or PBS.
2.3.4. IgG Fc Conjugation Studies
After NP formation and purification, IgG Fc was conjugated to the NP surface using
maleimide-thiol chemistry. In general, the NPs were washed with water and then washed
with PBS to a final concentration of 10 mg/mL. Concurrently, 5 mg/mL IgG Fc in PBS was
reacted with 5 mg/mL 2-iminothiolane, or Traut's Reagent (TR), in PBS for 1 hr at room
temperature. The modified IgG Fc was added to the NPs and mixed. The IgG Fc-targeted NPs
(NP-Fc) were washed with PBS using Millipore Amicon Ultra 100,000 NMWL. Several
reaction parameters were studied to evaluate the effect on the IgG Fc conjugation. The
molar ratio of TR to IgG Fc was varied from 0-80x and the modified IgG Fc was added to the
NPs at a IgG Fc to PLA-PEG molar ratio of 5% with no EDTA added and reacted at 40C for 1
hr. The concentration of EDTA added to the NPs after washing with PBS and to the IgG Fc
during the reaction with TR was studied by varying the concentration from 0-100 mM. In the
EDTA experiments, the TR to IgG Fc molar ratio was 40x. The modified IgG Fc was reacted
with the NPs at a IgG Fc to PLA-PEG molar ratio of 5% for 1 hr at 40C. The IgG Fc to NP
conjugation reaction time and temperature were also studied. The reaction time was varied
from 1 to 22 hr with the other parameters held constant: TR to IgG Fc molar ratio of 40x, IgG
Fc to PLA-PEG molar ratio of 5%, and a reaction temperature of 40C. The reaction
temperature was tested at 40C and 25 0C with the other parameters held constant: TR to IgG
Fc molar ratio of 40x, IgG Fc to PLA-PEG molar ratio of 5%, and a reaction time of 2 hr. The
conjugation of IgG Fc to the NP surface was measured after washing away the free IgG Fc by
collecting 500 [tg of NPs and measuring the protein concentration using a protein
bicinchoninic acid (BCA) assay from Lamda Biotech.
2.3.5. Particle Stability Studies
For the particle stability studies, the NPs were prepared by dissolving PLA-PEG in
acetonitrile at 10 mg/mL and adding the polymer solution dropwise into water with a
solvent to water volume ratio of 1:4. The mixture was stirred for 2 hr at room temperature
before the NPs were purified by filtration using Millipore Amicon Ultra 100,000 NMWL
membranes and washed with water and then PBS with 5 mM EDTA and collected at a
concentration of 10 mg/mL. Concurrently, 5 mg/mL IgG Fc in PBS with 5 mM EDTA was
reacted with 5 mg/mL TR in PBS with 5 mM EDTA for 1 hr at room temperature. The
modified IgG Fc was then added to the NPs and mixed at a molar ratio of IgG Fc to PLA-PEG
of 0.3% for 1 hr at 40C. The NP-Fc were then washed with PBS either at pH 2 or pH 6 using
Millipore Amicon Ultra 100,000 NMWL. 500 tg of NPs and NP-Fc were collected at each
time point from both the pH 2 and pH 6 buffers and the particle size was measured using
dynamic light scattering with a Brookhaven Instruments ZetaPALS at a temperature of 25 0C
and a scattering angle of 900 with a NP concentration of 0.1 mg/mL
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2.4. RESULTS
2.4.1. Polymer Synthesis
PLA-PEG diblock copolymers were synthesized using ring-opening polymerization (29, 30).
Heterobifunctional PEG with hydroxyl and maleimide end groups (HO-PEG-MAL) and a
molecular weight of 3.4 kDa was obtained and DL-lactide was polymerized from the
hydroxyl-terminated end of the PEG using tin(II) 2-ethylhexanoate as a catalyst (Figure 2.3).
The molecular weigh of the PLA block was controlled by varying the molar ratio of PEG
polymer to lactide monomer prior to the polymerization reaction. After synthesis and
purification, the structure of the polymer was determined using IH NMR (Figure 2.4).
2.4.2. NP Size
There have been several studies demonstrating that intestinal absorption of NPs is
enhanced as particle size decreases (31, 32), although these studies have focused on non-
targeted NP oral delivery. Furthermore, electron tomography studies of the FcRn
transcytosis pathway have revealed that IgG Fc is transported through a complex network of
entangled tubular and irregular vesicles that vary in size from 60-150 nm (33). Therefore,
particle size was identified as an important parameter of the NP delivery system with a
target NP size of less than 100 nm. Because of the size target, the NPs were formulated
using the nanoprecipitation method.
Several different formulation parameters were studied to achieve the target size, including
the polymer molecular weight, polymer concentration in the solvent phase, the ratio of
solvent to aqueous phase volumes, and the amount of PLGA blended with PLA-PEG. In
addition, the solvent used was also examined. For nanoprecipitation, a water-miscible
solvent is required. Typically, acetonitrile is used because it is water-miscible and volatile,
evaporating from the solution during the mixing step of the process (28). However, for oral
delivery applications, biologics such as insulin are potential cargoes of the NPs and are not
soluble in acetonitrile. Therefore, DMSO was used for much of the NP development
because both polymers and biologic molecules are soluble in the solvent and can be mixed
together prior to nanoprecipitation to facilitate drug encapsulation (24).
The first parameters examined for NP development were the PLA block molecular weight
and the solvent. Two different molecular weights were generated, 13 kDa and 35 kDa, by
using lactide:PEG molar ratios of 130 and 420, respectively (Table 2.1). With all other
formulation parameters held constant, the NP diameter and polydispersity were both
smaller when using the lower molecular weight polymer. For the 13 kDa PLA-PEG polymer,
the effect of solvent was also investigated by comparing the NPs generated using either
acetonitrile or DMSO as the solvent. The results indicated that there was only a slight
increase in both NP diameter and polydispersity when using DMSO instead of acetonitrile.
Polymer concentration in the solvent was investigated by preparing PLA-PEG concentrations
in DMSO ranging from 1 to 50 mg/mL. The different concentrations were used to generate
NPs with the nanoprecipitation method while all other formulation parameters were held
constant. Based on the results, lower polymer concentrations resulted in smaller NP
diameters (Figure 2.5).
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The ratio of solvent volume to water volume was also investigated by varying the
DMSO:water volume ratio from 1:11 to 1:1 with all other nanoprecipitation formulation
parameters held constant. The results indicated that there was an optimal ratio in the range
of 1:5 to 1:3 to achieve minimal NP size, with higher or lower ratios resulting in increases in
the NP size (Figure 2.6).
PLGA, because of the glycolic acid monomers incorporated into the polymer, is more
hydrophilic than PLA (34). Because biologics used for oral delivery are usually hydrophilic, it
was hypothesized that incorporating PLGA into the NP core would increase the
hydrophilicity of the core and improve biologic encapsulation. The lack of PEG conjugated to
PLGA would also provide a means of controlling the amount of PEG on the surface of the
NPs and the number of maleimide groups available for conjugation with IgG Fc molecules.
Therefore, the effect of the blending ratio of PLGA:PLA-PEG on NP size was studied. The
PLGA used had a lactide:glycolide ratio of 50:50 and a molecular weight of 5 kDa. Several
different blending ratios, measured in terms of the mass of PLGA relative to the mass of
PLA-PEG, were prepared ranging from 0 to 50% (wt%). NPs were prepared using the
nanoprecipitation method with all other formulation parameters held constant. The results
indicated that the blending ratio of PLGA to PLA-PEG had no significant effect on the NP size
(Figure 2.7).
After the nanoprecipitation self-assembly process, the NPs were purified by filtering them
through a 100 kDa membrane using centrifugation. Once the purification was complete,
some larger aggregates were typically observed (Figure 2.8A). To remove these larger
aggregates and prepare the NPs for in vivo administration, the NPs were further filtered
using a 0.1 [tm filter, resulting in a more uniform NP population (Figure 2.8B). The average
NP diameter decreased from 82.7 +/- 2.8 nm to 52.0 +/- 1.3 nm (average +/- SD, n=3) and
the polydispersity decreased from 0.360 +/- 0.012 to 0.058 +/- 0.041 (average +/- SD, n=3)
as a result of the filtration.
2.4.3. IgG Fc Conjugation
To target the NPs to the FcRn, the IgG Fc fragment was conjugated to the NP surface.
Conjugation, rather than physical absorption, was necessary because the NPs would pass
through many different environments during oral delivery, including a range of different pH
values and salt concentrations (35). Conjugation ensured that the IgG Fc remained with the
NPs and that the amount of Fc on the surface remained constant. Polyclonal IgG Fc
fragments were obtained from a vendor, mitigating the need to treat IgG antibodies with
proteases and purify the Fc fragment. The IgG Fc was conjugated to the NP surface by first
treating the IgG Fc with 2-iminothiolane, or Traut's Reagent (TR), to convert primary amines
on the IgG Fc surface to thiol groups (36). The thiol-modified IgG Fc were then added to NPs
with maleimide groups on the surface, resulting in the thiol adding across the double bond
of the maleimide to yield a thioether covalent bond (Figure 2.9).
Several formulation parameters were investigated in order to achieve efficient conjugation
of IgG Fc to the NP surface, including the molar ratio of TR to IgG Fc, the addition of EDTA to
prevent disulfide crosslinking, and the time and temperature necessary for the conjugation
reaction. The first parameter investigated was the molar ratio of TR to Fc. IgG Fc was
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treated with different molar ratios of TR, ranging from 0 to 80, for 1 hr at room temperature
prior to incubation with the NPs. The amount of IgG Fc on the NP surface was measured
after the conjugation reaction and the results showed that there was an optimal ratio for
conjugation of 10 (Figure 2.10).
The next parameter investigated was whether the addition of EDTA prior to the thiol-
modification reaction and conjugation reaction affected the conjugation efficiency. The
hypothesis was that adding EDTA to the solution would prevent crosslinking of free thiol
groups on the Fc, resulting in more thiol groups available for reaction with the maleimide
groups. In addition, the EDTA could also prevent crosslinking of Fc between NPs, reducing
aggregation during the conjugation reaction. The amount of EDTA added was varied from 0
to 100 mM with all other conjugation parameters held constant, and the IgG Fc conjugated
to the NP surface was measured. The results suggested that the addition of EDTA did
improve the conjugation, but only at specific concentrations, which was 10 mM for this
experiment (Figure 2.11).
The reaction time and temperature for the thiol-maleimide conjugation reaction were also
studied to determine the optimal conditions for the IgG Fc conjugation. The reaction time
was studied by incubating the thiol-modified IgG Fc with NPs for different times ranging
from 1 to 22 hrs and then measuring the amount of IgG Fc on the NP surface with all other
conjugation parameters held constant. The results showed that the reaction was complete
after 1 hr and that further incubation did not result in significantly more IgG Fc conjugation
to the NP surface (Figure 2.12). For the temperature studies, the conjugation reaction was
carried out at 40C and 25 0C with all other conjugation parameters held constant. The results
showed that there was no significant difference in the IgG Fc amount on the NP surface at
the different temperatures (Figure 2.13).
The molar ratio of IgG Fc to PLA-PEG polymer was investigated as a parameter that could be
used to control the amount of IgG Fc present on the NP surface. Several different molar
ratios were tested ranging from 0 to 18%, with the molar ratio calculated as the number of
moles of IgG Fc added divided by the initial amount of polymer used to form the NPs. With
all other conjugation parameters held constant, the results showed that varying the molar
ratio resulted in different amounts of IgG Fc on the NP surface (Figure 2.14).
2.4.4. Particle Stability
Because the NPs will be exposed to a range of different conditions after oral administration,
it was important to investigate the stability of both non-targeted NPs and FcRn-targeted NPs
(NP-Fc). For this study, both NP and NP-Fc were incubated for up to 28 hrs in PBS solutions
with pH values of 2 to simulate the stomach or 6 to simulate the duodenum section of the
intestines. The particle stability was characterized by measuring changes in NP size over
time. The results demonstrated that both formulations were stable at pH 2 and 6 over the
entire timecourse of the study, although some increases in size were observed at 28 hr
(Figure 2.15). However, the residence time in the stomach and duodenum should be
significantly less than 28 hr, so the size increases observed at later times should not be an
issue during actual administration.
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2.5. DISCUSSION
Oral delivery is a desirable route of injection because of the convenience to patients and
compliance with dosing regimens (37, 38). The goal of this study was to engineer NPs
capable of targeting the FcRn to facilitate intestinal transepithelial transport and achieve
efficient oral delivery. In order to be translatable to the clinic, the NPs were formed out of
biodegradable and biocompatible polymers. The PLA-PEG diblock copolymers were
synthesized using ring opening polymerization, which allowed the molecular weight of the
PLA block to be controlled and provided flexibility in the design of the NPs.
One of the criteria for the NPs was a particle size less than 100 nm. To achieve these sizes,
the nanopecipitation self-assembly method was used instead of the double emulsion
method. In the nanoprecipitation method, the NP size is dependent on the rate at which the
aqueous phase diffuses into the organic phase, with faster diffusion resulting in smaller and
more uniform NPs (39, 40). Previous studies have demonstrated that by decreasing the
polymer concentration or the solvent:water volume ratio, NP sizes were reduced. Dissolving
the polymer in a solvent with higher water miscibility also reduced NP sizes (28).
The results from studies in this chapter generally agreed with previous studies. Two
solvents, acetonitrile and DMSO, were used to generate NPs. Both solvents are highly
soluble in water, with DMSO having a slightly higher polarity than acetonitrile. Therefore, it
was expected that the two solvents would generate NPs of similar size, which is what was
observed in the NP size studies. For future studies, either solvent could be used to generate
NPs. Acetonitrile offers the advantage of higher volatility, making purification of the NPs
easier by evaporating from the NP solution. DMSO offers the advantage that biologic
molecules are more soluble due to the higher polarity, allowing DMSO to be used in
applications where biologic molecules need to be encapsulated in the NPs. However, DMSO
is significantly less volatile than acetonitrile and requires more wash steps to purify the NPs.
Therefore, the selection of solvent may depend on the application, with biologic
encapsulation requiring DMSO while other applications utilizing acetonitrile.
Consistent with previous studies, it was observed that lower polymer concentrations in the
solvent phase resulted in smaller NP sizes. Therefore, to achieve the smallest particle sizes,
lower polymer concentrations should be used. However, in the case of DMSO, larger solvent
volumes require more wash steps to purify and increase the length of time of the
purification step. This would not be ideal, since encapsulated drugs will release from the
NPs during the wash, reducing the load of the drug in the NPs prior to administration.
Therefore, a trade-off may be necessary, with an intermediate polymer concentration used
that keeps the NP size below 100 nm while reducing the amount of solvent used to form the
NPs.
The solvent:water volume ratio trend was not consistent with previous studies. Previous
studies suggested that higher volumes of water relative to solvent would lead to faster
diffusion of water into the solvent phase, causing faster formation of NPs at smaller sizes
(28). However, in this study, there was an optimal volume ratio of DMSO:water observed
that was not the highest ratio of water to DMSO. Instead, DMSO:water ratios of 1:5 and 1:3
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led to the smallest sizes. The 1:1 ratio led to a larger particle sizes, possibly because with too
much DMSO present, the NPs did not form as rapidly. At ratios of 1:11 and 1:7, the particle
sizes were also larger. It is unclear why this was observed, but it may be due to the use of
DMSO rather than acetonitrile, which was used in other studies. Being able to use lower
volumes of water for NP formation is advantageous because it reduces the amount of
volume that needs to be filtered during the wash step, decreasing the total time for the
wash step.
The blending of PLGA with PLA-PEG offers some flexibility in the design of the NP delivery
system. First, it allows the hydrophobicity of the NP core to be manipulated since the
glycolide monomers of PLGA are more hydrophilic. By increasing the amount of PLGA in the
core, it may be possible to increase encapsulation of more hydrophilic molecules, such as
biologic molecules. The other design parameter that can be controlled is the amount of PEG
on the NP surface, which influences the stealth properties of the NPs and the surface
charge. It also dictates the number of maleimide groups available for conjugation with IgG
Fc, providing another option for controlling the IgG Fc density on the NP surface or
minimizing the number of free maleimide groups present after the conjugation of IgG Fc to
the NPs. The blending on PLGA with PLA-PEG had no effect on the NP size, providing more
flexibility in the NP design without changing the NP size.
Finally, for the particle size, filtration with a 0.1 [tm filter, which is necessary to make the
formulation sterile for administration, resulted in a more monodisperse population of NPs
and a smaller average size. This was achieved by removing larger populations of aggregates
that were over 100 nm and would be less capable of transport across the intestinal
epithelium.
For the IgG Fc conjugation, the objective was to achieve the most efficient conjugation
conditions while minimizing the potential for loss of payload due to drug release. This was
achieved by investigating several conjugation parameters. One of the key parameters was
the ratio of TR to IgG Fc, which corresponded to the number of thiol groups introduced onto
the IgG Fc surface. An optimal ratio of lIx was identified, with higher ratios resulting in
lower IgG Fc densities on the NP surface. The higher ratios may have resulted in too many
free thiol groups being introduced onto the IgG Fc surface, possibly resulting in disulfide
crosslinking. Crosslinking between IgG Fc molecules would result in less free thiols available
for conjugation, while crosslinking between IgG Fc molecules on different NPs would result
in NP aggregation. As the FcRn-targeted NPs are evaluated for interactions with the FcRn,
this parameter may need to be revisited. Too many thiol groups on the IgG Fc may result in
multiple bonds between one IgG Fc and several PEG, reducing the flexibility of the IgG Fc on
the NP surface and preventing the IgG Fc from reaching the proper orientation for
interaction with the FcRn.
In addition to controlling disulfide crosslinking with the TR:IgG Fc molar ratio, EDTA was also
added to the solution during the TR treatment of the IgG Fc and the conjugation reaction.
EDTA prevents disulfide crosslinking by chelating free metal ions in solution. An optimal
concentration of 10 mM was found for IgG Fc conjugation. Lower concentrations may not
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have been sufficient to prevent crosslinking, while higher concentrations may have
interfered with the conjugation reaction.
The time and temperature necessary for the conjugation reaction were studied to
determine the conditions under which the IgG Fc conjugation would be successful while
minimizing release of the NP payload. The payload would be encapsulated as part of the NP
formation step prior to IgG Fc conjugation. Shorter reaction times and lower temperatures
would slow the rate of release of the payload from the NPs, so these conditions were
studied. The results indicated that a 1 hr reaction at 40C was as efficient as reactions at
longer times and higher temperatures.
Finally, control of the IgG Fc density on the NP surface was demonstrated by varying the
molar ratio of IgG Fc to polymer used to form the NPs. The IgG Fc density could be an
important design parameter for the interaction with the FcRn, so control over the ligand
density was important.
NP stability was studied in solutions that mimic the pH conditions of the stomach (pH 2) and
the duodenum (pH 6). It was critical that NPs and NP-Fc were stable in these solutions, and
the results showed that the NP size did not change significantly over the incubation times
used, which were much longer than the residence time of NPs in either organ. Therefore,
NP-Fc stability in the stomach and duodenum should not be an issue for oral delivery
applications. This is consistent with other studies that have investigated PLA nanoparticle
stability in low-pH solutions (41).
In conclusion, NPs formed from biodegradable and biocompatible materials were developed
that meet the design criteria specified for FcRn-targeted NPs. NPs were engineered that
were less than 100 nm in diameter with IgG Fc conjugated to the surface as a targeting
ligand for the FcRn. Particle size studies identified several parameters that could be used to
control the NP size. Conjugation studies were able to identify the optimal conditions for IgG
Fc conjugation as well as demonstrate that the IgG Fc ligand density could be controlled.
Finally, the particles were shown to be stable under conditions mimicking the stomach and
duodenum. The next steps for this system are to test whether it is able to target the FcRn
and utilize the transcytosis pathway for transepithelial transport using in vitro and in vivo
models.
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Table 2.1. Effect of polymer molecular weight and solvent on NP size
using the nanoprecipitation self-assembly method*
130 13 Acetonitrile
420 35 Acetonitrile
130 13 DMSO
86.8+/- 1.1
126.6 +/- 0.4
94.1+/- 1.2
0.186 +/- 0.030
0.225 +/- 0.008
0.216 +1- 0.013
*Nanoprecipitation formulation parameters: PLA-PEG concentration = 10 mg/mL;
solvent:water volume ratio = 1:4. Polymer Mn measured using gel permeation
chromatography (GPC). Diameter and polydispersity measurements are average +/- SD, n=3.
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Figure 2.1. Schematic of FcRN-targeted NPs. The NPs were formed using a diblock
copolymer with a hydrophobic PLA block conjugated to a hydrophilic PEG block. The PLA
core is biodegradable and used for drug encapsulation and controlled release. The PEG
corona is involved in improved particle stability and increased blood circulation half-life. It
may also aid in intestinal epithelium mucus penetration. The targeting ligand is the IgG Fc
fragment conjugated to the PEG for targeting to the FcRn. The payload is flexible but could
consist of therapeutic or imaging agents either physically encapsulated or conjugated to the
PLA in the NP core.
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Figure 2.2. Self-assembly techniques for polymeric NP formation. In the nanoprecipitation
technique, polymer and drug are dissolved in a water-miscible solvent and added dropwise
to an aqueous solution to form NPs. In the double emulsion method, drug is dissolved in an
aqueous solution with a surfactant and emulsified in a water-immiscible solvent containing
the polymer. This first emulsion is added to a second aqueous solution with or without
surfactant to form the second emulsion. The solvent is evaporated to solidify the NPs.
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Figure 2.3. Ring opening polymerization of PLA-PEG. Lactide monomer is polymerized from
the hydroxyl-terminated end of PEG using tin(II) 2-ethylhexanoate as a catalyst to form PLA-
PEG with a terminal maleimide group.
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Figure 2.4. NMR characterization of PLA-PEG dissolved in deuterated DMSO. The PLA-PEG-
MAL was characterized by 1H NMR (400 MHz), d = 5.28-5.11 (br, -OC-CH(CH 3)O- in PLA), 3.62
(s, -CH 2CH 20- in PEG), 1.57-1.45 (br, -OC-CHCH 30- in PLA).
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Figure 2.5. Effect of PLA-PEG concentration in DMSO on NP diameter. NPs were prepared
using the nanoprecipitation method, with a DMSO:water volume ratio of 1:5. NP diameters
were measured using dynamic light scattering. Diameter measurements are average +/- SD,
n=3.
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Figure 2.6. Effect of DMSO:water volume ratio on NP diameter. NPs were prepared using
the nanoprecipitation method, with a polymer concentration of 50 mg/mL in the solvent.
NP diameters were measured using dynamic light scattering. Diameter measurements are
average +/- SD, n=3.
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Figure 2.7. Effect of blending PLGA with PLA-PEG prior to nanoprecipitation. NPs were
prepared using the nanoprecipitation method, with a polymer concentration of 10 mg/mL
and a DMSO:water volume ratio of 1:4. The PLGA had a G:L ratio of 50:50 and a molecular
weight of 5 kDa. NP diameters were measured using dynamic light scattering. Diameter
measurements are average +/- SD, n=3.
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Figure 2.8. Removal of aggregates from NP formulations using a 0.1 pm filter. The
histograms show the NP size population (A) prior to filtration and (B) after filtration with a
0.1 ptm filter. The average NP diameter decreased from 82.7 +/- 2.8 nm to 52.0 +/- 1.3 nm
and the polydispersity decreased from 0.360 +/- 0.012 to 0.058 +/- 0.041 as a result of the
filtration. NP diameters and polydispersities were measured using dynamic light scattering.
Diameter and polydispersity measurements are average +/- SD, n=3.
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Figure 2.9. Conjugation of IgG Fc fragment to NP surface. IgG Fc fragments were treated
with 2-iminothiolane, or Traut's Reagent (TR), which converts primary amines to thiol
groups. The thiols on the Fc then react with maleimide groups at the end of the PEG on the
surface of the NPs to form covalent thioether bonds.
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Figure 2.10. Effect of TR:lgG Fc molar ratio on the conjugation of IgG Fc to the NP surface.
IgG Fc was treated with different molar ratios of TR for 1 hr at room temperature prior to
the incubation with NPs at 40C for 1 hr. The molar ratio of IgG Fc to PLA-PEG was held
constant at 5% for each of the conjugation reactions and no EDTA was included in any of the
reactions. The IgG Fc on the NP surface was measured using the BCA protein assay, with the
data shown as average +/- SD, n=3.
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Figure 2.11. Effect of EDTA addition on the conjugation of IgG Fc to the NP surface. EDTA
was added to IgG Fc prior to treatment with TR and was also added at the same
concentration to NPs prior to the conjugation reaction. The TR treatment was for 1 hr at
room temperature with a TR:Fc ratio of 40x and the conjugation reaction was for 1 hr at 40C
with a IgG Fc to PLA-PEG molar ratio of 5%. The IgG Fc on the NP surface was measured
using the BCA protein assay, with the data shown as average +/- SD, n=3. .
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Figure 2.12. Effect of reaction time on the conjugation of IgG Fc to the NP surface. IgG Fc
was incubated with NPs for several different reaction times. The TR treatment was for 1 hr
at room temperature with a TR:Fc ratio of 40x and the conjugation reaction IgG Fc to PLA-
PEG molar ratio was 5%. EDTA was not used in this experiment. The IgG Fc on the NP
surface was measured using the BCA protein assay, with the data shown as average +/- SD,
n=3.
68
CC
-
z
to
E
to
40
EL
1.0 r
0.8
0.6
0.4i
0.2
0.0
4 25
Temperature (*C)
Figure 2.13. Effect of reaction temperature on the conjugation of IgG Fc to the NP surface.
IgG Fc was incubated with NPs at two different temperatures. The TR treatment was for 1 hr
at room temperature with a TR:Fc ratio of 40x and the conjugation reaction was for 2 hrs
with a IgG Fc to PLA-PEG molar ratio of 5%. EDTA was not used in this experiment. The IgG
Fc on the NP surface was measured using the BCA protein assay, with the data shown as
average +/- SD, n=3.
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Figure 2.14. Effect of the IgG Fc:Polymer molar ratio on the conjugation of IgG Fc to the NP
surface. The amount of IgG Fc relative to polymer used to form the NPs was varied and the
amount of IgG Fc conjugated to the NP surface measured. The TR treatment was for 1 hr at
room temperature with a TR:Fc ratio of 40x and the conjugation reaction was for 1 hr. EDTA
was not used in this experiment. The IgG Fc on the NP surface was measured using the BCA
protein assay, with the data shown as average +/- SD, n=3.
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Figure 2.15. Particle stability of NP and NP-Fc at various pH conditions. NP and NP-Fc were
incubated in pBS at pH 2 and pH 6 over time and the particle size measured at specific
timepoints by dynamic light scattering. The NP diameter measurements are the average +/-
SD, n=3.
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Chapter 3: Transepithelial Transport of IgG Fc-Targeted Nanoparticles by
the Neonatal Fc Receptor for Oral Delivery
3.1. ABSTRACT
Nanoparticles are poised to have a tremendous impact on the treatment of many diseases,
but their broad application is limited because currently they can only be administered by
parenteral methods. Oral administration of nanoparticles is highly preferred but remains a
significant challenge because of the barriers presented by the gastrointestinal tract. In
particular, transport across the intestinal epithelium limits efficient oral delivery of
nanoparticles. In this chapter, it was demonstrated that nanoparticles targeted to the
neonatal Fc receptor, which is known to mediate the transport of IgG antibodies across
epithelial barriers, are efficiently transported across the intestinal epithelium using both in
vitro and in vivo models. Using an epithelial cell monolayer model for in vitro transport
studies, NP-Fc were observed to cross the monolayer at a rate twice that of non-targeted
NPs. This enhancement was mitigated by the addition of excess free IgG, indicating that the
transport was receptor-mediated. In a mouse model, fluorescently labeled targeted
nanoparticles were visually observed crossing the intestinal epithelium and entering the
lamina propria after oral administration. In addition, targeted nanoparticles labeled with 14C
and orally administered to mice crossed the intestinal epithelium and reached systemic
circulation with a mean absorption efficiency of 13.7% compared with only 1.2% for non-
targeted nanoparticles (P<0.001), demonstrating the potential of the targeted nanoparticles
as an oral drug delivery vehicle. The blood circulation time in mice after intravenous
injection was significantly reduced from 2.3 hr to 0.4 hr for targeted nanoparticles
compared with non-targeted nanoparticles, indicating that the presence of Fc on the NP
surface results in faster clearance of the nanoparticles
3.2. INTRODUCTION
Nanoparticles (NPs) have the potential to make a significant impact on the treatment of
many diseases, including cancer (1), cardiovascular disease (2), and diabetes (3). Many NP-
based therapeutics are now entering clinical trials or have been approved for use (1, 4),
including targeted polymeric NPs ((5), clinical trial NCT01478893) based on technologies
that were previously described (6, 7). However, the impact of NPs in the clinic may be
limited to a narrow set of indications because NP administration is currently restricted to
parenteral methods. Many diseases that could benefit from NP-based therapeutics require
frequent administration. Alternate routes of administration, particularly oral, are preferred
because of the convenience and compliance by patients (8, 9). Intestinal absorption of NPs
is highly inefficient because the physicochemical parameters of NPs prevent their transport
across cellular barriers such as the intestinal epithelium (10-12). To improve the absorption
efficiency of NPs and to make the oral administration of NPs practical in the clinic, new
strategies are necessary to overcome the intestinal epithelial barrier.
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The neonatal Fc receptor (FcRn) mediates IgG transport across polarized epithelial barriers
(13, 14). It was discovered as the receptor in the neonatal intestine that transports IgG in
breast milk from mother to offspring (15). However, FcRn is expressed into adulthood at
levels similar to fetal expression (16), playing an important role in immune surveillance and
adaptive immunity (17). In adults, FcRn is observed in the apical region of epithelial cells in
the small intestine and diffusely throughout the colon (18). FcRn is also expressed in the
vascular endothelium, blood-brain barrier, kidneys, liver, lungs, and throughout the
hematopoietic system (19-21). FcRn interacts with the Fc portion of IgG in a pH-dependent
manner, binding with high affinity in acidic (pH <6.5) but not neutral pH (pH -7.4) (22). The
intracellular trafficking of the IgG:FcRn complex has been conclusively demonstrated in the
rat intestine using IgG Fc labeled with 1.4-nanometer (nm) gold as a contrast agent for
electron tomography (23). The studies revealed that Fc is transported through a complex
pathway involving a network of entangled tubular and irregular vesicles in order to reach
the basolateral surface of the cell.
We hypothesized that targeting NPs to FcRn using IgG Fc fragments would allow orally
administered NPs to be transported across the intestinal epithelium (Figure 3.1). Because
the duodenum is acidic (24), IgG Fc on the surface of FcRn-targeted NPs (NP-Fc) should bind
to FcRn at the apical surface of absorptive epithelial cells, leading to receptor-mediated
endocytosis (25). In other sections of the intestine (jejunum and ileum) where the lumen pH
is not acidic, NP-Fc could be taken up by fluid phase pinocytosis and then interact with the
FcRn in endosomes that are acidic (14). During intracellular trafficking, the NP-Fc:FcRn
complex passes through acidic compartments, resulting in continued binding. On the
basolateral side, exocytosis results in exposure to a neutral pH environment in the lamina
propria, causing the release of NP-Fc (26). NP-Fc can then diffuse through the lamina
propria and enter systemic circulation.
Fc-fusion proteins have been used to overcome biological barriers: Fc fused with
erythropoietin was measured in non-human primates after pulmonary administration (27);
and follicle-stimulating hormone fused with Fc reached circulation after oral delivery in
newborn rats (28). However, NPs offer several potential advantages over fusion proteins
including (i) transport of many drug molecules with each transcytosis event; (ii) protection
of drug molecules, particularly protein therapeutics, through encapsulation; and (iii)
mitigation of the need for drug modification. Yet no studies have used drug-encapsulated
NPs to target the FcRn for oral drug delivery applications.
In this chapter, the first example of NPs crossing an epithelial barrier in vivo using the FcRn
transcytosis pathway is demonstrated. Polymeric NPs surface-modified with Fc are shown to
target FcRn, resulting in transepithelial transport both in vitro and in vivo. NP-Fc
demonstrated enhanced transport specifically mediated by FcRn across an intestinal
epithelial monolayer in vitro. In mice, NP-Fc were imaged crossing the intestinal epithelium
and entering the lamina propria after oral administration. NP-Fc were also measured in
several organs after oral administration, indicating that NP-Fc were able to reach systemic
circulation. Finally, the blood clearance rate after intravenous injection in mice was
measured and showed that the presence of Fc on the NP surface caused faster clearance of
the NPs.
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3.3. MATERIALS AND METHODS
3.3.1 Materials
Human recombinant insulin and D,L-lactide was from Sigma-Aldrich. Poly(lactic acid) (PLA)
with terminal carboxylate groups (inherent viscosity 0.50 dL/g, MW -36 kDa) was from
Lactel. Maleimide PEG hydroxyl (MAL-PEG-OH, MW 3500) was from JenKem Technology.
Purified human polyclonal IgG Fc fragment prepared by papain digestion was from Bethyl
Laboratories. Alexa Fluor 647 hydrazide tris(triethylammonium) salt was from Invitrogen.
4C Doxorubicin HCI and 3H-PLGA were from Perkin Elmer. Rabbit anti-human FcRn, rabbit
anti-mouse FcRn, and goat anti-rabbit IgG-HRP were from Santa Cruz Biotech. Caco-2 cells
were from American Type Culture Collection (ATCC).
3.3.2. Synthesis of Polymers
D,L-lactide and MAL-PEG-OH were used to synthesize PLA-PEG-MAL by ring opening
polymerization- D,L-lactide (3 g, 20.8 mmol) and MAL-PEG-OH (544 mg, 0.16 mmol) were
dissolved in 15 mL anhydrous toluene in a round bottom flask. Tin(II) ethylhexanoate (38
mg, 0.09 mmol) was then added. The flask with condenser was placed in an oil bath, purged
with nitrogen for 10 minutes, heated to 1200 C, and reacted overnight while 40C water
circulated through the condenser. Toluene was then evaporated and the polymer
precipitated in a mixture of ice-cold methanol and diethyl ether and vacuum-dried. The PLA-
PEG-MAL was characterized by 1H NMR (400 MHz), d = 5.28-5.11 (br, -OC-CH(CH 3)O- in PLA),
3.62 (s, -CH 2CH 20- in PEG), 1.57-1.45 (br, -OC-CHCH 30- in PLA). Using GPC, the polymer Mn =
12.5 kDa with M, / Mn = 1.47 relative to polystyrene standards.
PLA conjugated to 14C Doxorubicin (PLA- 14C) and Alexa Fluor 647 (PLA-AF647) were prepared
the same way. PLA in dimethylformamide (DMF) was reacted with N-hydroxysuccinimide
(NHS) in the presence of 1-Ethyl-3-[3-dimethylaminopropyl] overnight. PLA-NHS was
precipitated in a mixture of ice-cold methanol and diethyl ether and vacuum-dried. For PLA-
4C, PLA-NHS (18 mg, 0.5 pimol) was mixed overnight with 14C Doxorubicin (0.27 mg, 0.5
imol) in DMF. For PLA-AF647, PLA-NHS (50 mg, 1.4 tmol) was mixed overnight with Alexa
Fluor 647 (1.5 mg, 1.4 Imol) in DMF. Both polymers were precipitated in a mixture of ice-
cold methanol and diethyl ether and vacuum-dried.
3.3.3. Synthesis and Characterization of NP-Fc
To prepare the NP-Fc, PLA-PEG was dissolved in acetonitrile at 10 mg/mL and added
dropwise to water with an acetonitrile:water ratio of 1:4. The solution was mixed for 2 hr,
and the NPs were purified by filtration using Millipore Amicon Ultra 100,000 NMWL. The
NPs were washed with water and phosphate-buffered saline (PBS) containing 5 mM EDTA.
Concurrently, 5 mg/mL IgG Fc in PBS containing 5 mM EDTA was reacted with 5 mg/mL 2-
iminothiolane (Traut's Reagent) for 1 h at a molar ratio of 10x (Traut's Reagent to IgG Fc).
The modified IgG Fc was added to the NPs at a molar ratio of 0.8% (IgG Fc to PLA-PEG) and
mixed for 1 hr to allow conjugation at 40C. The NP-Fc were washed with PBS using Millipore
Amicon Ultra 100,000 NMWL. The conjugation of IgG Fc to the NP surface was measured by
sampling 500 [tg of NP-Fc and measuring the protein concentration using a protein
bicinchoninic acid (BCA) assay from Lamda Biotech. Particle diameter and surface charge
(zeta potential) were measured using dynamic light scattering with a Brookhaven
74
Instruments ZetaPALS of 500 [ig samples of NP and NP-Fc at a concentration of 0.1 mg/mL
in either water or PBS. Transmission electron microscopy (TEM) images were obtained by
negative staining of the NPs at 1 mg/mL with 3% uranyl acetate.
3.3.4. In vitro Transcytosis Studies
Transepithelial transport studies utilized Transwell plates (Costar) with a Caco-2 cell density
of 5.5 x 104 in media (ATCC formulated Eagle's Minimum Essential Medium with aqueous
penicillin G (100 units/mL), streptomycin (100 units/mL), and fetal bovine serum (FBS,
20%)). On the day of the transport experiment, the media was changed to HBSS pH 6.5 in
the apical chamber and HBSS pH 7.4 in the basolateral chamber and allowed to equilibrate
for 1 h at 370 C and 5% CO 2. Prior to the experiment, the monolayer integrity was checked by
measuring the transepithelial resistance (TEER) using a Millicell-ERS (Millipore). 3H-labeled
NPs were prepared by blending 3H-PLGA with PLA-PEG-MAL in acetonitrile prior to
nanoprecipitation. The apical solution was then replaced with a solution of 3H-labeled NPs
or NP-Fc in HBSS pH 6.5. The NP formulations were incubated for 24 h before measuring the
3H content in the basolateral chamber. The basolateral solution was collected and added to
a Hionic-Fluor scintillation cocktail (Perkin Elmer) before analysis using a Packard Tri-Carb
Scintillation Analyser. At the end of the experiment, the TEER was measured again to verify
monolayer integrity. For the IgG blocking experiment, 50x excess IgG relative to Fc from NP-
Fc was added with NP-Fc to the apical chamber, and the 3H content in the basolateral
chamber was measured after 24 h.
3.3.5. Western Blot
Small intestine and colon were removed from wild-type mice after euthanasia. Intestinal
epithelial cells were removed, and protein was extracted and separated on 12% SDS-PAGE.
The primary antibodies were rabbit anti-human FcRn or rabbit anti-mouse FcRn, and the
secondary antibody was goat anti-rabbit IgG-HRP. Detection was by chemiluminescence.
3.3.6. Immunohistochemistry
Small intestine tissues were harvested and fixed in 10% formalin overnight. After ethanol
dehydration, tissues were paraffin embedded and cut into 8 stm-thick sections, mounted on
slides, and dried overnight. The tissues were then rehydrated using xylene and ethanol.
Endogenous peroxidase activity, endogenous biotin, and nonspecific proteins were blocked
with 3% H2 02, avidin blocking agent, and 10% goat serum, respectively. The samples were
incubated with primary antibody overnight, then incubated with biotinylated secondary
antibodies, with streptavidin-HRP, developed with DAP, and mounted with hematoxylin
counterstain.
3.3.7. In vivo Fluorescence Imaging
All animal studies were conducted under the supervision of MIT's Division of Comparative
Medicine in compliance with the NIH's Principles of Laboratory Animal Care. Wild-type
Balb/c mice (Charles River Laboratories) (n=3/group) were fasted overnight prior to gavage.
Fluorescently-labeled NPs were prepared by blending 10% (weight %) of PLGA-AF647 with
PLA-PEG-MAL in acetonitrile prior to nanoprecipitation to form fluorescently-labeled NP and
NP-Fc. 1.5 hr after oral gavage, mice were euthanized, and duodenum tissues were
collected, frozen into block with OCT, cryosectioned, and mounted with DAPI. Tissue
75
fluorescence was visualized by confocal fluorescence microscopy (Zeiss 710 LSM NLO) for
DAPI (excitation = 358 nm; emission = 461 nm) and NPs (excitation = 594 nm; emission =
614 nm) at 25x and 40x magnification.
3.3.8. In vivo Biodistribution
To prepare 14C-labeled NP-Fc, PLA- 14C was blended with PLA-PEG-MAL in acetonitrile prior
to nanoprecipitation. 14C release was measured using the same method as for insulin
release. 6-12 week old wild-type mice were fasted 8 hr prior to oral gavage of 1.5 mg (0.1
p.Ci/mouse) of 14C-labeled NP and NP-Fc in PBS. Groups of mice were euthanized at each
time point, and the spleen, kidneys, liver, lungs, and heart were harvested. Each organ was
placed directly in a scintillation vial except for the liver, which was homogenized and "100
mg was analyzed. Each organ was solubilized in 2 mL of Solvable (Perkin Elmer) for 12 hr at
600 C and then decolored with 200 ptL of 0.5 M EDTA (Invitrogen) and 200 pL 30% hydrogen
peroxide (Fisher Scientific) for 1 hr at 600C. The activity was counted in Hionic-Fluor
scintillation cocktail using a Packard Tri-Carb Scintillation Analyser. To determine 100%
dose, vials of NPs and NP-Fc were counted. For the oral absorption efficiency, total 14C
counted in all tissues was added at each time point. The AUC of total absorbed 14C versus
time was calculated using the trapezoid method and divided by the initial dose to determine
the oral absorption efficiency. The results were reported as mean ± SEM, and comparison of
non-targeted NPs and NP-Fc utilized the two-tailed Student's t-test
3.3.9. In vivo Pharmacokinetics
Fluorescently-labeled NPs were prepared by blending 15% (weight %) of PLGA-AF647 with
PLA-PEG-MAL in acetonitrile prior to nanoprecipitation. Fluorescently-labeled NP and NP-Fc
were suspended in PBS at 25 mg/mL and 5 mg were administered by tail-vein injection to 6-
12 week old wild-type Balb/c mice (n=4 mice/group). Approximately 5 min after
administration, blood was collected by retro-orbital bleeding to estimate the initial
fluorescence in the blood. Further blood samples were taken at 30 min, 1, 2, 4, 7, 16, 24 hr.
Fluorescence in the blood was measured using an IVIS whole animal imaging system
(Xenogen) with excitation at 640 nm and emission at 700 nm. The fluorescence for the NP
and NP-Fc samples were corrected for background signal by collecting blood from mice
intravenously administered PBS only and measuring the fluorescence to establish the
autofluorescence signal of the blood.
3.4. RESULTS
3.4.1 Preparation of Fc-Targeted NPs
NPs were formed from biodegradable and biocompatible poly(lactic acid)-b-polyethylene
glycol (PLA-PEG) block copolymers. PLA is a biodegradable polymer used in many FDA-
approved products and forms the NP core due to its hydrophobicity (29). PEG is a
biocompatible polymer that remains on the NP surface due to its hydrophilic nature and
forms the NP corona. PLA-PEG was synthesized using ring-opening polymerization with a
free terminal maleimide group (PLA-PEG-MAL) to conjugate the Fc portion of IgG.
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Studies of NPs have shown enhanced intestinal uptake as particle size decreases (30, 31).
However, previous studies have mostly focused on nonspecific uptake by M cells in the
Peyer's patches as opposed to specifically targeting the NPs to a transcytosis pathway such
as the FcRn-mediated pathway. Here, the nanoprecipitation self-assembly method (32)
(Figure 3.2) was used to generate particles with a mean hydrodynamic diameter of 55 nm
and a polydispersity of 0.05 (Figure 3.3A). TEM images confirmed the particle size and
monodisperse nature of the NP-Fc (Figure 3.3B).
Polyclonal IgG Fc fragments were covalently conjugated to PEG using maleimide-thiol
chemistry. 2-iminothiolane was used to modify the Fc fragment with thiol groups (Fc-SH).
Fc-SH was incubated with NPs for conjugation (Figure 3.2). The amount of Fc conjugated to
the NPs was measured for both Fc-SH and unmodified Fc (Figure 3.4). Unmodified Fc
resulted in low ligand density, indicating minimal nonspecific interactions between Fc and
the NP surface and that the unbound Fc was successfully separated from NP using
centrifugal filtration. Conversely, the ligand density for Fc-SH was 32 times higher than
unmodified Fc, indicating that Fc was bound on the NP surface. In addition, the
hydrodynamic diameter of the NP increased from 55 nm to 63 nm after Fc conjugation
(Figure 3.3A), an increase consistent with the hydrodynamic diameter of IgG Fc (-3 nm) (33).
The surface charge showed only a minor change with the addition of Fc to the NP surface
(Figure 3.5).
3.4.2. In vitro Transepithelial Transport
In vitro NP transepithelial transport studies were conducted using an epithelial cell
monolayer model with Caco-2 cells, a human epithelial colorectal adenocarcinoma cell line
typically used as a model of the intestine for drug permeability testing (Figure 3.6). Caco-2
cells endogenously express human FcRn and human P2-microglobulin and have previously
been used for IgG transcytosis studies (14, 34). 3 H-labeled NPs were used to measure
transport across the Caco-2 monolayer. Using this system with a pH gradient established
from the apical to basolateral side of the Caco-2 polarized monolayer to mimic the
physiological pH of the duodenum and enhance apical binding, the transcytosis of non-
targeted NPs (control) and NP-Fc was measured. The NP-Fc had two times higher 3H
measurements on the basolateral side compared with non-targeted NPs after 24 hr,
indicating that Fc on the NP surface significantly enhanced transepithelial transport in vitro
(Figure 3.7). When NP-Fc was combined with a 50x excess of free IgG as a blocking agent for
the FcRn transcytosis pathway, NP-Fc transport was reduced significantly, indicating that the
enhanced transport of NP-Fc was receptor-mediated.
3.4.3. FcRn Expression in Mice
FcRn expression in the intestinal tissue of wild-type mice was confirmed by Western blot
(Figure 3.8A). FcRn is expressed in the entire small and large intestine, with the highest
expression in the duodenum and the lowest expression in the colon. Immunohistochemistry
techniques showed that FcRn was localized to the epithelium of the intestinal villi of the
duodenum of wild-type mice (Figure 3.8B).
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3.4.4. In vivo Absorption and Biodistribution
In vivo transport of NP-Fc across the intestinal epithelium was visualized using fluorescently
labeled NPs. Fasted wild-type mice were orally administered the fluorescently labeled NPs,
and the intestines were collected and analyzed using confocal fluorescent microscopy.
Representative images for both non-targeted NPs (Figure 3.9A) and NP-Fc (Figure 3.9B) are
shown, with higher fluorescence intensity observed in the tissue for NP-Fc compared with
non-targeted NPs. Imaging using a higher magnification (40x) revealed NP-Fc inside and on
the basolateral side of the epithelial cells, indicating that NP-Fc crossed the intestinal
epithelium and entered the lamina propria of the intestinal villi (Figure 3.9C).
The biodistribution and absorption efficiency of both targeted and non-targeted NPs were
quantitatively measured by radiolabeling the NPs with 14C, which showed no significant
release over 24 hr (Figure 3.10). Figure 3.11 shows the biodistribution of non-targeted NPs
and NP-Fc over time after oral administration to fasted wild-type mice. For the non-targeted
NPs, a small amount of 14C was measured in the organs. By contrast, a large amount of 14C
was measured in the spleen, kidneys, liver, and lungs for NP-Fc, indicating that NP-Fc
entered systemic circulation after oral administration and reached several organs known to
express FcRn (19). The 14C in the organs was transient, peaking at 2.5 h post-administration
and clearing from the organs at later time points. The total 14C absorbed over time was
calculated by summing the 14C measured in all of the organs at a specific time point (Figure
3.12). Significantly higher amounts of 14C were absorbed for NP-Fc at 1.5, 2.5, and 4 hr
compared with non-targeted NPs, indicating that Fc targeting enhanced absorption. The
area under the curve (AUC) was used to calculate the oral absorption efficiency, which was
1.2% ± 0.2 for non-targeted NPs and 13.7% ± 1.3 for NP-Fc (mean ± SEM with n=5 mice, P <
0.01), suggesting that Fc targeting was responsible for an 11.5x increase in absorption.
3.4.5. In vivo Pharmacokinetics
The pharmacokinetics of fluorescently-labeled non-targeted NPs and NP-Fc after
intravenous tail-vein injection was studied in wild-type mice. Blood samples were collected
by retro-orbital bleeding at several timepoints after injection and quantified. The presence
of Fc on the NP surface resulted in a faster clearance rate when compared with non-
targeted NPs (Figure 3.13). The blood circulation half-life was calculated to be 2.3 hr for
non-targeted NPs, but only 0.4 hr for NP-Fc.
3.5. DISCUSSSION
For many diseases, oral administration of therapeutics is the standard of care because daily
therapy is required. In some cases, chronic diseases, such as cancer, that have been treated
in the clinic with intravenous infusions are now increasingly being treated with oral
therapeutics because patients prefer the convenience of oral administration relative to
parenteral administration (35). For NP-based therapeutics to be a practical treatment of
many diseases, NP formulations appropriate for oral administration are necessary. The most
significant barrier to the effective oral administration of NPs is the intestinal epithelium,
which limits the absorption of NPs. To date, there is no practical solution to this problem.
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We have taken a novel approach to address this problem by developing NPs capable of
targeting FcRn for transepithelial transport and enhanced NP intestinal absorption after oral
administration. FcRN has been shown to mediate the transcytosis of IgG across several
epithelial and endothelial barriers (19), and more recently the transcytosis of fluorescent
NPs was demonstrated across a monolayer of Calu-3 airway epithelial cells in vitro after
adsorption of Fc on the NP surface (40). Harnessing the transcytosis pathway to cross the
intestinal epithelium offers the advantage of leaving intact the integrity of the epithelial
barrier, avoiding potential safety issues and adverse effects associated with manipulating
the permeability of the intestine for paracellular or transcellular transport (12). An
additional advantage of targeting the FcRn is that this receptor is expressed throughout the
intestine, providing a significant increase in the available absorption surface area for NP-Fc,
which is in contrast with other drug delivery systems that target only a specific portion of
the intestine such as the Peyer's patches (10).
We have demonstrated that targeting FcRn for transepithelial transport by modifying the
NP surface with IgG Fc provides a successful approach for the oral delivery of NPs. Using a
mouse model, we demonstrated that FcRn enabled the NP-Fc to cross the intestinal
epithelium and reach systemic circulation. Rodents significantly downregulate the FcRn
expression in the intestine after weaning (41), but humans continue to express FcRn into
adulthood. Therefore, while NP-Fc can increase transepithelial transport in mice, the
transport in humans could potentially be even more efficient.
While modifying the NP surface with IgG Fc to target the FcRn resulted in enhanced
transepithelial transport, there are some drawbacks to using an antibody for targeting.
There are many different Fc receptors present in the body that could bind the Fc on the NP
surface (42, 43). Once inside the body, NPs covered with IgG Fc resemble many viruses in
both shape and size and the presence of antibodies on the surface may be a signal to the
immune system to remove the NPs from the body. This was observed in the
pharmacokinetics study, where NP-Fc were cleared from the blood much more rapidly than
non-targeted NPs. Further design of the system will need to address this in order to improve
the efficacy of the system.
This novel technology may have a major impact on the treatment of several diseases by
enabling NP-based therapies to be orally administered. In addition, the encapsulation of
drugs or biologics that are currently limited by low bioavailability into NPs that target FcRn
may enable markedly more efficient oral delivery of the therapies. In the future,
immunological responses to Fc on the NP surface need to be investigated, and NP-Fc may
have oral vaccine applications (44, 45). The technology described here has the potential to
be expanded for drug delivery across other cellular barriers known to express FcRn, such as
the vascular endothelium, blood-brain barrier, kidney, liver, and lung (19).
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Figure 3.1. Fc-targeted nanoparticles are transported across the intestinal epithelium by
the FcRn through a transcytosis pathway. (1) IgG Fc on the NP surface binds to the FcRn on
the apical side of absorptive epithelial cells under acidic conditions in the intestine. In other
sections of the intestine where the lumen pH is not acidic, NP-Fc could be taken up by fluid
phase pinocytosis and then interact with the FcRn in endosomes that are acidic (2) NP-Fc
are then trafficked across the epithelial cell through the FcRn transcytosis pathway in acidic
endosomes. (3) Upon exocytosis on the basolateral side of the cell, the physiological pH
causes IgG Fc to dissociate from the FcRn and NP-Fc are free to diffuse through the lamina
propria to the capillaries or lacteal and enter systemic circulation.
84
Protein
. p-medifed Mndn
wnd uph"k of NP-Fc by
Intastinal .umen (pH 6.0) * Inteaft Lu"Mn P  6.0) NP-FC
Fcltn
I,
Q...g..2 -g '"" r
'ftJ' PLA-PEG-maleimide Dissolve in acetonitrile or DMSO
Payload
Add dropwise into
aqueous solution
Wash off
free drug
Nanoprecipitation
iSH
Conjugation
Pof Fc-SH
NP NP-Fc
Figure 3.2. Schematic of NP assembly and Fc conjugation. NPs consist of a biodegradable
PLA core for drug encapsulation and controlled release and a PEG surface coating for
particle stability and to reduce phagocytic uptake. NPs were formed using the
nanoprecipitation self-assembly method and surface-modified with IgG Fc for FcRn
targeting.
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Figure 3.3. NP and NP-Fc particle size. (A) Dynamic light scattering measurements for non-
targeted NPs and NP-Fc (data expressed as mean ± SD, n=3). (B) TEM images of NPs
negatively stained with 3% uranyl acetate.
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Figure 3.4. IgG Fc conjugation to NP surface. IgG Fc ligand density on the NP surface with
(Fc-SH) and without (Fc) thiol modification of the IgG Fc (data expressed as mean ± SD, n=3).
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Figure 3.5. Surface charge of NP and NP-Fc. The zeta potential of NP and NP-Fc was
measured in PBS at 0.1 mg/mL (data expressed as mean ± SD, n=3).
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Figure 3.6. Schematic of epithelium cell monolayer model transport studies. Caco-2 cells
were grown on a semipermeable membrane in Transwell plates until tight junctions were
formed as measured by TEER. A pH gradient was established across the monolayer with pH
6 in the apical chamber and pH 7.4 in the basolateral chamber. 3H-labeled NPs and NP-Fc
were added to the apical chamber and the basolateral chamber was sampled over time to
measure the 3H using a scintillation counter.
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Figure 3.7. In vitro NP transepithelial transport studies. In vitro transepithelial transport of
non-targeted NPs, NP-Fc and NP-Fc with an excess of human IgG as a blocking agent for
FcRn. The results are expressed as the mean basolateral 3H disintegrations per minute
(DPM) as a percentage of the initial amount of 3H ± SEM for n = 4 wells per group. *P < 0.05
using a two-tailed Student's t-test.
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Figure 3.8. FcRn expression in mice. (A) Western blot of mouse FcRn (mFcRn) in mouse
intestinal tissue (B) Immunohistochemistry on sections of mouse duodenum with mFcRn
stained brown. Magnification at 10x and 60x are shown with the negative control in the left
panels.
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Figure 3.9. Fluorescence imaging of NP-Fc transepithelial transport in vivo. NPs labeled
with Alexa Fluor 647 dye were administered to wild-type mice by oral gavage and the
intestines were collected 2 hr after administration. Sections of intestine were frozen in OCT,
cryosectioned, and mounted on slides using mounting medium containing DAPI. Tissues
were imaged using confocal fluorescence microscopy with DAPI (blue) and NPs (pink). (A)
Fluorescence image of sectioned mouse intestine at 25x magnification for non-targeted
NPs. (B) Fluorescence image of sectioned mouse intestine at 25x magnification for NP-Fc. (C)
Fluorescence image of an intestinal villi with NP-Fc at 40x magnification.
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Figure 3.10. 1C release from NPs. Release of 14C from 14C-labeled NPs in PBS at 370C. Data
represent mean ± SD for n=2 separate release experiments.
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Figure 3.11. Biodistribution of NP and NP-Fc after oral gavage to wild-type mice.
Biodistribution of 14C-labeled non-targeted NPs (left) and NP-Fc (right) after oral
administration to fasted wild-type mice. Data represent the mean % initial dose (ID) per
gram of tissue ± SEM with n=5 mice per time point.
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Figure 3.12. Intestinal absorption of NP and NP-Fc after oral gavage to wild-type mice.
Total absorbed 4C over time for non-targeted NPs and NP-Fc after administration by oral
gavage. Data represent the mean %ID measured in all of the organs added together ± SEM
with n=5 mice per time point. *P < 0.01 for comparison of non-targeted NPs and NP-Fc at
corresponding time point using a two-tailed Student's t-test.
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Figure 3.13. Pharmacokinetics of NP and NP-Fc after tail-vein injection to wild-type mice.
Fluorescently-labeled NPs and NP-Fc were administered to mice by tail-vein injection and
blood samples were collected and measured for fluorescence. Data represents the percent
of fluorescence in the blood relative to the initial fluorescence measured in the blood (C/Co)
± SD with n=4 mice per group.
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Chapter 4: Oral Delivery of Insulin using Polymeric Nanoparticles Targeted
to the Neonatal Fc Receptor
4.1. ABSTRACT
Biologics are being increasingly used for the treatment for a wide range of diseases. The
treatment of these diseases typically requires frequent intravenous administration of high
doses of the biologic. Alternate routes of administration, particularly oral, are considered
favorable because of improved convenience and compliance by patients, but physiological
barriers such as extreme pH, enzyme degradation, and poor permeability across the
intestinal epithelium limit absorption. Encapsulating biologics in drug delivery systems such
as polymeric nanoparticles (NPs) reduces degradation caused by low pH and enzymes of the
gastrointestinal (GI) tract. However, transport across the intestinal epithelium remains the
most critical barrier to overcome for efficient oral delivery. In this chapter, Fc-targeted NPs
(NP-Fc) containing a biologic therapy and targeted to the neonatal Fc receptor (FcRn) for
intestinal transepithelial transport were developed. The methods developed in previous
chapters to form NP-Fc were modified to encapsulate a model biologic, insulin. Several
formulation parameters were studied, including the insulin to polymer ratio and effect of
poly(lactic-co-glycolic acid) (PLGA), in order to develop the first example of an insulin-
encapsulated NP with particle size less than 100 nanometers (nm). The insulin encapsulated
NP-Fc (insNP-Fc) were orally administered at a clinically relevant insulin dose of 1.1 U/kg
and elicited a prolonged hypoglycemic response in wild-type mice. This effect was abolished
in FcRN knockout mice, indicating that enhanced transport of insNP-Fc was due specifically
to FcRn. The effect of the IgG Fc surface density on the in vivo efficacy was studied, and it
was found that an optimal IgG Fc density exists to maximize the hypoglycemic response in
wild-type mice. Protease inhibitors were also added to the insNP-Fc formulation to improve
the efficacy, but the presence of the inhibitors had no significant effect on the hypoglycemic
response.
4.2. INTRODUCTION
Biologics, including hormones, antibodies, growth factors, enzymes, and vaccines, are being
increasingly used for the treatment of numerous diseases ranging from cancer to rare
genetic disorders (1). The majority of biologic products are injection-based therapies that
require frequent treatments over prolonged periods of time (2). Alternate routes of
administration such as oral delivery are considered more favorable because of improved
convenience and compliance by patients, ultimately resulting in improved treatment
efficacy (3, 4). However, biologics are often proteins and nucleic acids that face many
physiological barriers along the gastrointestinal (GI) tract that limit their absorption,
including extreme pH environments, enzymatic degradation, and poor permeability across
the intestinal epithelium (5). Encapsulation of biologics inside polymeric NPs allows the
therapeutic agent to be shielded from the low pH environment and enzymes of the GI tract
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(6). However, there are currently no strategies that efficiently overcome the intestinal
epithelium barrier and achieve systemic absorption of biologics (7).
In chapter 3, efficient transepithelial transport of NPs was demonstrated by targeting the
NPs to the FcRn. NP-Fc were able to utilize the FcRn transcytosis pathway to overcome the
intestinal epithelium transport barrier. Using a mouse model, orally administered NP-Fc
were observed crossing the intestinal epithelium and entering the lamina propria. The NP-Fc
were also measured in several organs, including the liver, lungs, and spleen, indicating that
the NP-Fc reached systemic circulation.
In this chapter, using insulin as a model biologic and diabetes as a model disease, NP-Fc
were developed to efficiently deliver a bioactive biologic after oral administration. The NPs
were developed from the same polymeric NPs engineered in chapter 2 and evaluated in
chapter 3 using the biocompatible and biodegradable poly(lactic acid)-b-polyethylene glycol
(PLA-PEG) block copolymers to form the NPs and modifying the surface with IgG Fc to target
the FcRn. Insulin was encapsulated by optimizing several formulation parameters, including
the insulin to polymer weight ratio and PLGA blending ratio prior to nanoprecipitation. The
encapsulated insulin demonstrated controlled release over 10 hr in a bioactive form while
the NPs maintained a size less than 100 nm. The insulin-encapsulated NP-Fc were orally
administered to wild-type mice at a clinically relevant insulin dose of 1.1 U/kg and elicited a
prolonged hypoglycemic response. This effect was abolished in FcRN knockout mice,
indicating the enhanced nanoparticle transport was due specifically to FcRn. The effect of
the IgG Fc density on the NP surface was studied and an optimal density for generating a
hypoglycemic response in mice was observed. Finally, the addition of protease inhibitors to
the formulation proved to have no effect on the efficacy of the insulin-encapsulated NP-Fc.
4.3. MATERIAL AND METHODS
4.3.1. Materials
Human recombinant insulin, casein from bovine milk, and DL-lactide were from Sigma-
Aldrich. Poly(lactic-co-glycolic acid) (PLGA) with 50:50 G:L ratio and terminal carboxylate
groups (inherent viscosity 0.20 dL/g, MW -5 kDa) and poly(lactic acid) (PLA) with terminal
carboxylate groups (inherent viscosity 0.50 dL/g, MW -36 kDa) were from Lactel. Maleimide
PEG hydroxyl (MAL-PEG-OH, MW 3500) was from JenKem Technology. Purified human
polyclonal IgG Fc fragment prepared by papain digestion was from Bethyl Laboratories.
Dimethyl sulfoxide (DMSO), dichloromethane (DCM), acetonitrile, and tin(II) 2-
ethylhexanoate were from Sigma-Aldrich.
4.3.2. Synthesis of Polymers
DL-lactide and MAL-PEG-OH were used to synthesize PLA-PEG-MAL by ring opening
polymerization. DL-lactide (3 g, 20.8 mmol) and MAL-PEG-OH (544 mg, 0.16 mmol) were
dissolved in 15 mL anhydrous toluene in a round bottom flask. Tin(II) ethylhexanoate (38
mg, 0.09 mmol) was then added. The flask with condenser was placed in an oil bath, purged
with nitrogen for 10 minutes, heated to 1200 C, and reacted overnight while 40C water
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circulated through the condenser. Toluene was then evaporated and the polymer
precipitated in a mixture of ice-cold methanol and diethyl ether and vacuum-dried. The PLA-
PEG-MAL was characterized by 1H NMR (400 MHz), d = 5.28-5.11 (br, -OC-CH(CH 3)O- in PLA),
3.62 (s, -CH 2CH 20- in PEG), 1.57-1.45 (br, -OC-CHCH 30- in PLA). Using GPC, the polymer Mn =
12.5 kDa with M, / M, = 1.47 relative to polystyrene standards.
4.3.3. Synthesis and Characterization of NP-Fc
To prepare the NP-Fc, PLA-PEG was dissolved in acetonitrile at 10 mg/mL and added
dropwise to water with an acetonitrile:water ratio of 1:4. The solution was mixed for 2 hr,
and the NPs were purified by filtration using Millipore Amicon Ultra 100,000 NMWL. The
NPs were washed with water and phosphate-buffered saline (PBS) containing 5 mM EDTA.
Concurrently, 5 mg/mL IgG Fc in PBS containing 5 mM EDTA was reacted with 5 mg/mL 2-
iminothiolane (Traut's Reagent) for 1 h at a molar ratio of 10x (Traut's Reagent to IgG Fc).
The modified IgG Fc was added to the NPs at a molar ratio of 0.8% (IgG Fc to PLA-PEG) and
mixed for 1 hr to allow conjugation at 40C. The NP-Fc were washed with PBS using Millipore
Amicon Ultra 100,000 NMWL. The conjugation of IgG Fc to the NP surface was measured by
sampling 500 tg of NP-Fc and measuring the protein concentration using a protein
bicinchoninic acid (BCA) assay from Lamda Biotech. Particle diameter and surface charge
(zeta potential) were measured using dynamic light scattering with a Brookhaven
Instruments ZetaPALS of 500 [tg samples of NP and NP-Fc at a concentration of 0.1 mg/mL
in either water or PBS. Transmission electron microscopy (TEM) images were obtained by
negative staining of the NPs at 1 mg/mL with 3% uranyl acetate.
4.3.4. Insulin Encapsulation and Release
For the insulin encapsulation studies, insulin NPs (insNPs) were prepared by mixing insulin
with PLA-PEG and PLGA in DMSO prior to nanoprecipitation. The insulin/polymer solution
was added dropwise to water with a DMSO:water volume ratio of 1:4 and mixed for 2 hr at
room temperature. Free insulin was removed using Millipore Amicon Ultra 100,000 NMWL.
Insulin encapsulation was measured by two possible methods: (1) insNPs were lyophilized
overnight and treated with a 50:50 mixture of DCM and 0.1 N HCI, with the 0.1 N HCI phase
containing insulin collected, or (2) insNPs were heated at 600C for 30 min and allowed to
cool. Insulin was quantified using a BCA assay or insulin ELISA kit (Millipore). Formulation
parameters were varied to study the effects on insulin encapsulation. The insulin to polymer
weight ratio was studied by mixing insulin at 5 mg/mL in DMSO with a solution of PLA-PEG
blended with 15% (wt%) PLGA in DMSO at a polymer concentration of 10 mg/mL using
insulin to polymer weight ratios ranging from 0-30% (wt%) prior to nanoprecipitation. PLGA
blending was studied by mixing PLGA with PLA-PEG at weight ratios ranging from 0-50%
(wt%) using a polymer concentration of 10 mg/mL in DMSO. The mixtures were added to 5
mg/mL insulin in DMSO with an insulin to polymer ratio of 1% (wt%) prior to
nanoprecipitation. For the insulin ionization studies, insulin was solubilized in water
buffered to pH values of 4, 6, and 7.4. Each solution was then lyophilized overnight and
dissolved in DMSO at 5 mg/mL. Each solution was then added to a mixture of PLA-PEG
blended with 15% (wt%) PLGA in DMSO at 10 mg/mL using an insulin to polymer ratio of
30% (wt%) before nanoprecipitation.
99
For the release and in vivo studies, insNPs were prepared by dissolving insulin in DMSO at 5
mg/mL and adding it to a mixture of PLA-PEG blended with 15% (wt%) PLGA in DMSO at 10
mg/mL using an insulin to polymer ratio of 30% (wt%) prior to nanoprecipitation. Free
insulin was removed using Millipore Amicon Ultra 100,000 NMWL. Insulin encapsulation
was measured by heating the NPs to 600 C for 30 min, and insulin was measured using a BCA
assay or insulin ELISA kit (Millipore). Insulin release from insNPs was measured by dividing a
batch of insNPs equally into 24 kDa dialysis units (Pierce) and incubating at 370C in PBS with
pH 7.4. At each timepoint, three samples of insNP were collected, washed with PBS using
Millipore Amicon Ultra 100,000 NMWL, heated to 600C for 30 min, and measured for insulin
using a BCA assay.
4.3.5. Insulin Activity
All animal studies were conducted under the supervision of MIT's Division of Comparative
Medicine in compliance with the NIH's Principles of Laboratory Animal Care. Insulin activity
was measured by preparing insNPs and allowing insulin release for 2 h at 370 C in PBS at pH
7.4. Wild-type mice were fasted for 8 hr, and the mice (3/group) used were chosen so that
the mean initial blood glucose levels were the same for each group. After two hours, 3.3
U/kg of released insulin was administered to the fasted mice by tail-vein injection. An
equivalent dose of free insulin by mass was administered by tail-vein injection to another
group of fasted mice. The blood glucose level was measured using the Contour blood
glucose monitor (Bayer).
4.3.6. In vivo Efficacy
6-12-week old wild-type and FcRn knockout mice (Jackson Laboratories) were fasted for 8
hr. 6 mice were chosen per group such that the mean initial blood glucose levels were the
same per group. To prepare the insNP-Fc, IgG Fc was conjugated to the insNPs using an Fc to
polymer molar ratio of 0.8%. 250 pg of insNP or insNP-Fc (insulin dose - 1.1 U/kg) were
administered to the mice by oral gavage. For controls, 1.1 U/kg of free insulin and 250 pg of
NP-Fc without insulin were administered by oral gavage. The blood glucose level was
measured as described above.
The IgG Fc ligand density was studied by preparing insNPs and conjugating IgG Fc to the
surface using Fc to polymer molar ratios of 0.1, 0.4, and 1.0%. 6-12-week old wild-type
(Jackson Laboratories) were fasted for 8 hr. 5 mice were chosen per group such that the
mean initial blood glucose levels were the same per group. To prepare the insNP-Fc, IgG Fc
was conjugated to the insNPs using an Fc to polymer molar ratio of 0.8%. 250 Ig of each
insNP-Fc formulation (insulin dose - 1.1 U/kg) were administered to the mice by oral gavage.
The blood glucose level was measured as described above.
Casein was formulated with insNP-Fc by adding 625 ug of casein to the 250 ug insNP-Fc
(insulin dose - 1.1 U/kg). 6-12-week old wild-type (Jackson Laboratories) were fasted for 8
hr. 5 mice were chosen per group such that the mean initial blood glucose levels were the
same per group. The casein/insNP-Fc formulation was administered to the mice by oral
gavage. The blood glucose level was measured as described above.
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4.4. RESULTS
4.4.1. Insulin Encapsulation
Encapsulation of hydrophilic molecules such as insulin is usually done using the double
emulsion method because it allows insulin to be dissolved in an aqueous solution prior to
encapsulation (8). However, the double emulsion method results in particle sizes greater
than 100 nm (9, 10). Therefore, the nanoprecipitation self-assembly method was used to
form NPs from PLA-PEG. Nanoprecipitation requires that both the polymer and biologic be
soluble in the same water-miscible organic solvent. For this study, DMSO was used because
both PLA-PEG and insulin were soluble in it (8). In the nanoprecipitation method, NPs are
formed instantly upon dropwise addition of the organic phase solution into an aqueous
phase due to rapid solvent displacement, resulting in smaller particle sizes (typically less
than 100 nm) without the need for sonication or homogenization (11). During NP formation,
insulin was encapsulated in the PLA core followed by a wash step to separate
unencapsulated insulin from the NPs.
To improve the insulin load in the NPs, several different formulation parameters were
investigated, including the insulin to polymer weight ratio, PLGA blending, and the
ionization state of insulin. The first parameter evaluated was the weight ratio of insulin to
polymer in DMSO prior to nanoprecipitation. Different weight ratios of insulin to polymer
were prepared ranging from 0-30% (wt%) and used to form insulin NPs (insNPs) with all
other formulation parameters held constant. For this study, insNPs were generated by
adding insulin in DMSO to a solution of PLA-PEG blended with 15% (wt%) PLGA in DMSO
prior to nanoprecipitation. Based on the data, higher ratios of insulin to polymer resulted in
higher insulin loads (Figure 4.1).
PLGA, because of the glycolic acid monomers incorporated into the polymer, is more
hydrophilic than PLA (12). Since insulin is hydrophilic, incorporating PLGA into the NP core
should increase the hydrophilicity of the core and potentially improve insulin encapsulation.
To test this, several different weight ratios of PLGA to PLA-PEG were prepared in DMSO
ranging from 0-50% (wt%). The polymer solutions were mixed with insulin in DMSO solution
at a 1% (wt%) ratio of insulin to polymer prior to nanoprecipitation. The resulting insNPs
were analyzed for particle size and insulin load. The results of this study showed that
increasing the ratio of PLGA to PLA-PEG increased the insulin load over the entire blending
ratio range studied (Figure 4.2). The increase in insulin load did not lead to a significant
increase in particle size (Figure 4.3).
The ionization state of insulin was also investigated to improve the insulin load. If insulin
had less net charge, then potentially more insulin would encapsulate in the hydrophobic NP
core. To evaluate this, the ionization state of insulin was changed by varying the solution
pH, with pH values closer to the isoelectric point of insulin (pH -5.3) resulting in a more
neutral charge (13). The concept of "pH memory" was used to prepare insulin at different
ionization states for nanoprecipitation. pH memory refers to a protein's ability to reflect the
pH of the last aqueous solution to which it was exposed prior to lyophilization (14). Insulin
was dissolved in aqueous solutions with varying pH values in order to change the ionization
state of the insulin. The insulin was then lyophilized and dissolved in DMSO. The different
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insulin solutions were added to a mixture of PLGA blended with PLA-PEG at 15% (wt%) using
an insulin to polymer ratio of 30% (wt%) prior to nanoprecipitation. The data in Table 4.1
indicated that when insulin was prepared at pH 6 or 7.4, the resulting NPs had the same
diameter, but the load was significantly higher at pH 7.4 relative to pH 6. Insulin prepared at
pH 4 resulted in no NP formation.
After achieving insulin encapsulation through optimization of the formulation parameters,
the issue of whether the insulin was actually encapsulated in the core of the NPs or
associated with the surface was investigated. Insulin on the surface would still be exposed
to the low pH environment and proteases present in the GI tract, as well as it would not be
subject to the controlled release rate caused by diffusion of insulin from the NP core. To
evaluate this, the insulin load measurements were compared between insNPs washed with
water or PBS. Washing with PBS should weaken the electrostatic interaction between
insulin and the NP surface, causing surface-associated insulin to be removed during the
washing step. The data in Table 4.2 showed that a significant amount of insulin was lost
when the insNPs were washed with PBS, indicating that most of the insulin measured when
only water was used to wash the insNPs was on or near the surface of the insNPs.
The Fc conjugation step is performed after insulin encapsulation, and could potentially be a
source of significant insulin loss due to release from the NPs. Therefore, insulin loss across
the conjugation step was evaluated. The conditions used to simulate the Fc conjugation
reaction were 40C for 1 hr in PBS with 5 mM EDTA added. The insulin load of the insNPs was
measured before and after the incubation. The data showed that while there was some
insulin loss across the conjugation step, there was still insulin present in the insNPs at the
end of the step (Table 4.3). Using a lower temperature and only 1 hr for the conjugation
may have reduced the loss of insulin.
The method used to extract insulin from insNPs for insulin quantification was also
evaluated. Initially, the extraction method used involved lyophilizing insNPs and then
treating them with a 50:50 solution of DCM and 0.1 N HCI. DCM solubilized the polymer,
while the insulin was soluble in HCI. Since DCM and HCI were immiscible, the HCI phase was
collected to measure the insulin using the BCA assay. A second method was also
investigated using heat to accelerate the release of encapsulated insulin. insNPs were
incubated for 30 min at 600 C immediately after washing, allowed to cool, and then
measured for insulin using the BCA assay. The two methods were compared to determine
which measured the higher amount of insulin, and the data showed that the heating
method resulted in a higher insulin load measurement (Table 4.4).
4.4.2. Characterization of Encapsulated Insulin
Insulin release from insNPs was measured at 370C in PBS at pH 7.4. The results of the
release study showed that there was a strong burst release in the first hour followed by a
controlled release (Figure 4.4). The release rate is advantageous based on the
biodistribution data from the previous chapter (Figures 3.11 and 3.12) because it should
allow all of the insulin to be delivered before complete NP clearance.
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To determine the bioactivity, insulin released from insNPs was collected and injected into
fasted wild-type mice by tail-vein injection. The bioactivity was measured by monitoring the
blood glucose and comparing the response to an equivalent dose of free insulin solution.
The released insulin generated a hypoglycemic response in mice (Figure 4.5), indicating that
the encapsulated insulin was bioactive after release. Furthermore, the response for the
released insulin was the same as for free insulin, revealing that the released insulin was fully
bioactive.
4.4.3. In vivo Oral Delivery of Insulin
For the in vivo studies, insNPs were prepared by blending 15% (wt%) PLGA with PLA-PEG in
DMSO and adding the mixture to insulin in DMSO at an insulin to polymer ratio of 30%
(wt%) prior to nanoprecipitation. IgG Fc was then conjugated to the insNPs to form IgG Fc-
targeted insNPs (insNP-Fc) with an IgG Fc to polymer molar ratio of 0.8%. The resulting
insNP-Fc had an insulin load of 0.5% (wt%) and a mean NP diameter of 57 nm prior to
administration.
The hypoglycemic response generated after oral administration of the insNP-Fc was tested
using wild-type mice and compared with the efficacies of non-targeted insNPs, free insulin,
and NP-Fc without insulin (Figure 4.6). Neither the free insulin nor NP-Fc without insulin
generated a glucose response. The glucose response generated by non-targeted insNPs was
not significantly different from that generated by the control groups. However, insNP-Fc
generated a hypoglycemic response in the mice with an insulin dose of 1.1 U/kg, reducing
the glucose during the first 10 hr after administration, consistent with the biodistribution
and insulin release data, which demonstrated that the particles were cleared and the insulin
was released within 10 hr, respectively. The blood glucose level then increased and was
similar to that of the control groups by 15 hr.
The role of FcRn in insNP-Fc transepithelial transport was tested by repeating the efficacy
experiment using FcRn knockout (KO) mice (15). FcRn KO mice had the same insulin
sensitivity as the wild-type mice, so the same insulin dose (1.1 U/kg) was used for both
strains (Figure 4.7). In contrast to the results in the wild-type mice, insNP-Fc did not
generate a hypoglycemic response significantly different from the other three groups in the
FcRn KO mice (Figure 4.8). In fact, in the FcRn KO mice, the response generated by insNP-Fc
resembled the response generated by non-targeted insNPs in the wild-type mice, suggesting
that the benefit gained from using IgG Fc targeting was specifically due to FcRn.
The influence of the IgG Fc surface density was studied by preparing insNP-Fc with different
amounts of IgG Fc on the surface and evaluating the hypoglycemic response in wild-type
mice. The IgG Fc to polymer molar ratios studied were 0.1, 0.4, and 1.0% and the insulin
dose was 1.1 U/kg. The results showed that the IgG Fc density influenced the hypoglycemic
response (Figure 4.9). The 0.4% molar ratio resulted in the strongest hypoglycemic
response, while the 0.1% and 1.0% molar ratios had similar responses that were significantly
weaker than the 0.4% molar ratio.
The use of protease inhibitors formulated with the insNP-Fc was tested in wild-type mice.
Casein, a component of milk, has been shown to inhibit intestinal protease activity (16, 17).
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The hypoglycemic response of mice to insNP-Fc formulations with and without casein was
measured. The data indicated that there was no benefit from the presence of casein in the
formulation, suggesting that IgG Fc is not very susceptible to protease degradation (Figure
4.10).
4.5. DISCUSSION
Oral administration of biologics represents a significant challenge in the field of drug
delivery. There have been many attempts to develop oral drug delivery systems that
overcome the barriers presented by the GI tract (7, 18). For example, protease inhibitors
have been co-administered with protein therapeutics to prevent protease degradation (19).
Permeation enhancers have been used to open tight junctions to allow both paracellular
and transcellular transport of drugs across the epithelium (20). Mucoadhesive biomaterials
have been used to increase the retention time and local concentration of drugs near the
apical surface of epithelial cells (21). Many oral NPs have been engineered for uptake by M
cells in the Peyer's Patches, although this limits the surface area available for absorption
and exposes NPs to underlying immune cells (22). Finally, a few NP formulations have
targeted cell receptors, but they still suffer from low bioavailability and require high oral
drug dosages (18).
Several FcRn-targeting IgG Fc fusion proteins have been used to overcome biological
barriers: the fusion of IgG Fc with erythropoietin was measured in the serum of mice or non-
human primates after pulmonary administration (23); and follicle-stimulating hormone
fused with IgG Fc resulted in successful serum measurements after oral delivery in newborn
rats and pulmonary delivery in non-human primates (24). NPs offer several potential
advantages over fusion proteins, such as the ability to transport many biologics across the
epithelium with each transcytosis event, protection of sensitive biologics from the GI tract
through encapsulation, and NPs do not require modification of biologics. NPs also allow for
delivery to the bloodstream without extending the biologic's half-life beyond the
physiologic range in contrast to Fc-fusion proteins, which have this property because FcRn
prevents catabolism of IgG-based therapeutics (25). Recently, IgG Fc conjugated to the
surface of 20-50 nm fluorescent NPs were transported across an in vitro airway epithelial
cell monolayer (26). However, in vivo transport of NPs across biological barriers using FcRn-
mediated transcytosis has yet to be demonstrated and represents a novel approach to the
problem of delivering biologics through oral administration.
In this chapter, the FcRn-targeted NPs developed in chapters 2 and 3 were modified to
deliver a model biologic, insulin. The challenge with modifying the NPs was that there have
been no NPs developed that are under 100 nm and can encapsulate a biologic such as
insulin. All previous work used the double emulsion method for insulin encapsulation in
NPs, resulting in sizes typically between 150 and 200 nm or larger. Therefore, the
nanoprecipitation method used in the previous chapters for self-assembly of the NPs was
optimized to encapsulate insulin while maintaining a size below 100 nm. Several
formulation parameters, such as the insulin to polymer ratio, PLGA blending, and ionization
of insulin, were studied. Increasing the ratio of insulin to polymer increased the driving force
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for insulin entrapment by increasing the number of insulin molecules near polymer
molecules during the self-assembly process, resulting in higher insulin loads. Of course,
there was a trade-off because the higher ratio of insulin, while increasing the load, also
resulted in lower encapsulation efficiencies. Therefore, this is a parameter that would have
to be optimized to balance the insulin load with the amount of insulin lost in the process.
The other two parameters were manipulated to make the insulin more susceptible to
encapsulation. Increasing the ratio of PLGA increased the hydrophilicity in the core, which
should be a more favorable environment for the insulin. This was confirmed when the
increase in PLGA resulted in an increase in insulin load. This is another parameter that
would need to be further optimized since higher PLGA in the core increases the insulin load,
but also reduces the amount of PEG on the surface. PLGA-PEG could potentially be used
instead of PLA-PEG in the future and further optimized in terms of the molecular weight and
G:L ratio to further increase the insulin load. However, PLGA tends to have faster release
rates, which may not be favorable because the PLA core already has a fast insulin release
rate (27). The ionization state of insulin was also evaluated, but changing the net charge on
the insulin through changes in solution pH did not have a significant effect on load and
suggest that electrostatics are not the key parameter inhibiting greater insulin
encapsulation.
The optimized formulation parameters resulted in the development of the first example of
NPs encapsulating insulin under 100 nm. To achieve this using the nanoprecipitation
method, the insulin load was lower than what is typically possible with the double emulsion
technique. The release rate of insulin was also faster due to the smaller size and resulting
higher overall surface area of the NPs. However, the faster release rate worked well with
the delivery system since the data from chapter 3 showed that FcRn-targeted NP were
cleared after 8-10 hr, which was the timeframe over which the insulin was released from
the NPs.
The insNP-Fc were able to generate a significant hypoglycemic response with an insulin dose
of 1.1 U/kg, which is clinically relevant (2) and lower than other oral insulin delivery systems
(requiring 10-100 U/kg to generate a response) (18). When compared with the glucose
response from free insulin administered by tail vein injection (Figure 4.5), the orally
administered insNP-Fc resulted in a much more controlled and prolonged hypoglycemic
response, lasting up to 15 hr for insNP-Fc compared with only 2 hr for insulin administered
by tail vein injection. Therefore, this formulation could potentially act as long-lasting insulin
that could be taken orally and aid in maintaining glucose levels for most of the day. The
results from the FcRn KO mice indicated that the increased hypoglycemic response for the
insNP-Fc compared with non-targeted insNPs was specifically due to the FcRn.
The influence of IgG Fc surface density on the hypoglycemic response in mice suggested
that different Fc densities cause changes in the absorption or trafficking of NP-Fc. In these
studies, an optimal Fc density was identified, with higher and lower densities resulting in
less hypoglycemia in the mice. It was expected that increasing the density would result in a
greater response since more IgG Fc on the NP surface should increase the probability of
interactions between NP-Fc and the FcRn. However, the decline at the highest density was
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unexpected, and there are several potential explanations. Studies in human monocyte-
derived dendritic cells have shown that the number of IgG bound to an antigen influences
the intracellular trafficking of the antigen (28). In these studies, antigens with multiple IgG
bound to form multimeric immune complexes resulted in trafficking to lysosomes while
monomeric immune complexes were not trafficked to the lysosomes. Antigens with
multiple IgG antibodies mutated so they do not interact with the FcRn were not trafficked to
lysosomes either, indicating that the FcRn was directing the trafficking of multimeric
immune complexes to the lysosomes. While this has not been studied in epithelial cells, it is
possible that the higher Fc densities on the NP surface resulted in different intracellular
trafficking, possibly to the lysosomes rather than through the transcytosis pathway. Another
possible explanation is that the higher amount of IgG Fc on the NP surface affected the
diffusion of the NPs through the mucus layer overlaying the intestinal epithelial cells (29-
31). Studies of NP diffusion through human mucus have demonstrated that a high PEG
density increases the diffusion rate. Higher Fc densities may mitigate the PEG diffusion
enhancement effect, resulting in NP-Fc unable to reach the epithelial cells and interact with
the FcRn. Finally, the high Fc density may not affect transepithelial transport, but instead
could affect the biodistribution of the NPs once they enter circulation. Studies in mice with
xenograft tumors found that different ligand densities resulted in differences in tumor
accumulation, with high ligand densities resulting in less accumulation (32). Therefore, this
is a design parameter that could be explored to further improve the delivery system once
the underlying mechanism is identified.
The use of protease inhibitors in the oral formulation of the insNP-Fc was found to
ineffective, which may be due to several explanations. Studies of bovine immunoglobulins in
humans have shown that IgG antibodies are less susceptible to digestion than other
proteins (33), making them a good candidate ligand for oral delivery applications. The
conjugation of IgG Fc to PEG may also play a role in reducing the degradation rate by fixing
the orientation of the IgG Fc on the surface and providing a steric hindrance to proteases
(34). Avoiding protease inhibitors may be advantageous because, while protease inhibitors
have been studied for oral delivery (19), there is a toxic potential associated with the use of
protease inhibitors due to the incomplete digestion of nutrients. In addition, protease
inhibition may result in increased secretion of digestive enzymes as a result of feedback
regulation, leading to hypertrophy and hyperplasia of the pancreas (19, 35).
The technology developed in this chapter has the potential to have a major impact on the
treatment of several diseases by enabling biologic therapies to be orally administered. In
addition, the encapsulation of drugs that are currently limited by low bioavailability into NPs
that target FcRn may enable markedly more efficient oral delivery of the therapies.
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Table 4.1. Effect of insulin ionization state on insNP size and insulin load
4 n/a 0.00
6 56+/-0.5 0.02 +/- 0.002
7.4 56+/-0.7 0.10 +/- 0.1
insNPs were prepared by blending PLGA with PLA-PEG at 15% (wt%) in DMSO with a
polymer concentration of 10 mg/mL. The polymer solution was added to a solution of 5
mg/mL insulin in DMSO with a weight ratio of insulin to polymer of 30%. The solution of
insulin, PLGA, and PLA-PEG in DMSO was added dropwise to water with a DMSO:water
volume ratio of 1:4. The resulting insNPs were washed with PBS and water before
measuring the particle size using dynamic light scattering. Insulin was extracted by heat
treatment at 37 0C overnight and measured using the BCA assay. Insulin load was calculated
as the amount of encapsulated insulin measured divided by the amount of polymer used
based on weight. Diameter and insulin load measurements are average +/- SD, n=3.
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Table 4.2. Effect of wash step solution on insulin load
Water 3.43 +/- 0.4
PBS 0.44 +/- 0.01
insNPs were prepared by blending PLGA with PLA-PEG at 15% (wt%) in DMSO with a
polymer concentration of 10 mg/mL. The polymer solution was added to a solution of 5
mg/mL insulin in DMSO with a weight ratio of insulin to polymer of 30%. The solution of
insulin, PLGA, and PLA-PEG in DMSO was added dropwise to water with a DMSO:water
volume ratio of 1:4. The resulting insNPs were washed with either water or PBS. Insulin was
extracted by heat treatment at 600C for 30 min and measured using the BCA assay. Insulin
load was calculated as the amount of encapsulated insulin measured divided by the amount
of polymer used based on weight. Insulin load measurements are average +/- SD, n=3.
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Table 4.3. Effect of Fc conjugation step on insulin load
Pre-Fc Conjugation 0.44 +/- 0.06
Post-Fc Conjugation 0.30 +/- 0.05
insNPs were prepared by blending PLGA with PLA-PEG at 15% (wt%) in DM50 with a
polymer concentration of 10 mg/mL. The polymer solution was added to a solution of 5
mg/mL insulin in DMSO with a weight ratio of insulin to polymer of 30%. The solution of
insulin, PLGA, and PLA-PEG in DMSO was added dropwise to water with a DMSO:water
volume ratio of 1:4. The resulting insNPs were washed with PBS. Insulin was extracted by
heat treatment at 600C for 30 min and measured using the BCA assay. Insulin load was
calculated as the amount of encapsulated insulin measured divided by the amount of
polymer used based on weight. Insulin load measurements are average +/- SD, n=3.
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Table 4.4. Effect of insNP sample preparation on insulin load measurement
DCM:PBS Extraction 0.05 +1- 0.007
Heat - 600C, 30 min 0.44 +/- 0.06
insNPs were prepared by blending PLGA with PLA-PEG at 15% (wt%) in DMSO with a
polymer concentration of 10 mg/mL. The polymer solution was added to a solution of 5
mg/mL insulin in DMSO with a weight ratio of insulin to polymer of 30%. The solution of
insulin, PLGA, and PLA-PEG in DMSO was added dropwise to water with a DMSO:water
volume ratio of 1:4. The resulting insNPs were washed with PBS. insNPs were either
prepared by lyophilization and treatment with a 50:50 mixture of DCM and 0.1 N HCI or
heat treatment at 600C for 30 min. Insulin was measured using the BCA assay and the load
was calculated as the amount of encapsulated insulin measured divided by the amount of
polymer used based on weight. Insulin load measurements are average +/- SD, n=3.
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Figure 4.1. Effect of insulin to polymer weight ratio on insulin load in insNPs. insNPs were
prepared by adding insulin in DMSO at 5 mg/mL to a solution of PLA-PEG blended with 15%
(wt%) PLGA in DMSO with a polymer concentration of 10 mg/mL. The solution of insulin,
PLGA, and PLA-PEG in DMSO was added dropwise to water with a DMSO:water volume ratio
of 1:4. The resulting insNPs were washed with water, lyophilized, and a 50:50 mixture of
DCM and 0.1 N HCI was used to extract the encapsulated insulin from the NPs. Insulin was
measured using the BCA assay. Insulin load was calculated as the amount of encapsulated
insulin measured divided by the amount of polymer used based on weight. The data
represents the average +/- SD, n=2 experiments.
114
0.30
R0.25
0.20
.0 0.15 4
0.10
- 0.05
0.00
0 10 20 30 40 50
PLGA:PLA-PEG Ratio (wt %)
Figure 4.2. Effect of PLGA to PLA-PEG blending ratio on insulin load in insNPs. insNPs were
prepared by mixing PLGA and PLA-PEG in DMSO at specified weight ratios with a polymer
concentration of 10 mg/mL. The polymer solution was added to a solution of 5 mg/mL
insulin in DMSO with a weight ratio of insulin to polymer of 1%. The solution of insulin,
PLGA, and PLA-PEG in DMSO was added dropwise to water with a DMSO:water volume ratio
of 1:4. The resulting insNPs were washed with water, lyophilized, and a 50:50 mixture of
DCM and 0.1 N HCI was used to extract the encapsulated insulin from the NPs. Insulin was
measured using the BCA assay. Insulin load was calculated as the amount of encapsulated
insulin measured divided by the amount of polymer used based on weight. The data
represents the average +/- SD, n=2 experiments.
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Figure 4.3. Effect of PLGA to PLA-PEG blending ratio on insNP size. insNPs were prepared
by mixing PLGA and PLA-PEG in DMSO at specified weight ratios with a polymer
concentration of 10 mg/mL. The polymer solution was added to a solution of 5 mg/mL
insulin in DMSO with a weight ratio of insulin to polymer of 1%. The solution of insulin,
PLGA, and PLA-PEG in DMSO was added dropwise to water with a DMSO:water volume ratio
of 1:4. The resulting insNPs were washed with water and the NP diameters were measured
using dynamic light scattering. Diameter measurements are average +/- SD, n=3.
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Figure 4.4. Insulin release from insNPs. Release of insulin from insNPs at 370 C in PBS at pH
7.4. Data represent the mean ± SD with n=3 per time point.
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Figure 4.5. Bioactivity of insulin encapsulated in insNPs. Blood glucose response of fasted
wild-type mice to insulin encapsulated and released from NPs before administration and
free insulin administered by tail-vein injection at an insulin dose of 3.3 U/kg. Data represent
the mean ± SEM with n=3 mice per group.
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Figure 4.6. In vivo efficacy of insNP-Fc in wild-type mice after oral administration. Blood
glucose response of fasted wild-type mice to free insulin solution, NP-Fc containing no
insulin, non-targeted insNP, and insNP-Fc each administered by oral gavage with an insulin
dose of 1.1 U/kg. Data represent the mean ± SEM with n=6 mice per group. *P < 0.05 for
comparison of non-targeted insNP and insNP-Fc at corresponding time points using a two-
tailed Student's t-test.
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Figure 4.7. Comparison of blood glucose response in wild-type and FcRn KO mice. Blood
glucose response to equivalent insulin doses (3.3 U/kg) administered by tail-vein injection
into fasted wild-type and FcRn KO mice. Data represent mean ± SEM for n=3 mice per
group.
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Figure 4.8. In vivo efficacy of insNP-Fc in FcRn KO mice after oral administration. Fasted
FcRn KO mice blood glucose response to free insulin solution, NP-Fc containing no insulin,
non-targeted insNP, and insNP-Fc each administered by oral gavage with an insulin dose of
1.1 U/kg. Data represent the mean ± SEM with n=5 mice per group.
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Figure 4.9. Effect of IgG Fc surface density on in vivo efficacy of insNP-Fc after oral
administration. Fasted wild-type mice blood glucose response to insNP-Fc with different
amounts of IgG Fc conjugated to the surface after administration by oral gavage with an
insulin dose of 1.1 U/kg. Data represent the mean ± SEM with n=5 mice per group.
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Figure 4.10. Effect of protease inhibitor addition on in vivo efficacy of insNP-Fc after oral
administration. Fasted wild-type mice blood glucose response to insNP-Fc with and without
625 [tg of casein added to the formulation prior to administration by oral gavage with an
insulin dose of 1.1 U/kg. Data represent the mean ± SEM with n=5 mice per group.
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Chapter 5: Conclusions and Recommendations for Future Work
5.1. CONCLUSIONS
In this thesis, a novel approach was used to overcome the challenges of oral delivery by
developing nanoparticles (NPs) capable of targeting the neonatal Fc receptor (FcRn) for
transepithelial transport to enhance NP intestinal absorption after oral administration.
Formulation conditions were studied in order to develop a process capable of generating
FcRn-targeted NPs with sizes less than 100 nm, IgG Fc conjugated to the surface, and
capable of encapsulating and controllably releasing biologics, such as insulin, in a bioactive
form. In vitro and in vivo models were used to demonstrate that FcRn-targeted NPs were
capable of transepithelial transport due specifically to FcRn targeting. In mice models, FcRn-
targeted NPs were observed crossing the intestinal epithelium and reaching systemic
circulation after oral administration with a significantly higher absorption efficiency than
non-targeted NPs. FcRn-targeted NPs containing insulin as a model NP-based therapeutic
for diabetes were able to elicit a prolonged hypoglycemic response in mice after oral
administration using a clinically relevant insulin dose. The response was specifically due to
FcRn, as studies in FcRn knockout mice mitigated the enhanced response of the FcRn-
targeted NPs. This technology has the potential to have a major impact on the treatment of
many diseases by enabling NP-based therapies to be administered orally. In addition, the
encapsulation of drugs or biologics that are currently limited by low bioavailability into
FcRn-targeted NPs may enable markedly more efficient oral delivery of the therapies.
5.2. RECOMMENDATIONS FOR FUTURE WORK
While the FcRn-targeted NPs have demonstrated efficacy both in vitro and in vivo, there are
several aspects of the delivery system that could be studied to improve the efficiency of the
system and increase the potential for clinical translation. In addition, there are other
applications for this technology besides oral delivery that could be evaluated for feasibility.
One aspect of the system that could be improved is the insulin load in the NPs. The current
load achievable by the system, even after optimizing the formulation parameters, may be
too low for practical use in the clinic. One possible strategy that could be evaluated is to use
alternate polymers that could either replace poly(lactic acid) (PLA) or be introduced as a
third polymer block between PLA and polyethylene glycol (PEG). The third block could
consist of a peptide or polycation whose electrostatic and hydrophobic properties could be
engineered to increase interactions with insulin to facilitate greater insulin encapsulation.
The alternate polymers could also be screened to tune the insulin release profile for less
burst release.
Another aspect that could be further evaluated to improve the efficacy of the system is the
impact that the IgG Fc has on the biodistribution and pharmacokinetics of the NPs after
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intestinal absorption. IgG Fc on the NP surface is essential for targeting the FcRn and
utilizing the transcytosis pathway to cross epithelial cells. However, after absorption, the
IgG Fc may become a liability due to interactions with Fc receptors on immune cells, which
may cause rapid uptake of the NPs. There are a few potential strategies to mitigate this
liability. One strategy is to engineer the NPs to shed the IgG Fc once they enter the lamina
propria, exposing an inert PEG surface. The trigger for shedding could be based on pH or use
enzymes to cleave a linker. Matrix metalloproteinases (MMPs) could potentially be used to
shed the IgG Fc. The intestinal epithelium is a dynamic environment with a high turnover of
epithelial cells. As part of this turnover process, the components of the extracellular matrix
(ECM) are degraded and reconstructed. The degradation is accomplished by matrix
metalloproteinases (MMPs) that are either secreted into the extracellular space or bound to
the cell surface (1). Secreted MMPs, such as MMP-2 (gelatinase A) or MMP-9 (gelatinase B),
could potentially be used to degrade a linker connecting IgG Fc to PEG.
If shedding is not feasible, another potential strategy is to turn the NP delivery system into a
depot system once it crosses the epithelial barrier. To do this, a second ligand would be
attached to the NP surface that binds to some component of the extracellular matrix (ECM)
in the lamina propria. After anchoring to the ECM, the NPs could release insulin and the
insulin could enter systemic circulation through the capillaries. Since collagen IV represents
50% of all proteins in the ECM (2), it would be a good target. Future generations of the
depot system could also incorporate glucose-responsive polymers into the NP core so that
insulin release is controlled by the concentration of glucose in the surrounding
microenvironment (3).
Finally, a third potential strategy is to change the ligand. One possibility is to engineer the
IgG Fc fragment to be non-immunogenic. The other possibility is to screen for ligands that
bind FcRn in the same manner as IgG Fc. There have already been some studies that have
identified peptides that bind to FcRn (4, 5). A small molecule ligand would be ideal, as it
would be cheaper and simpler to use in a manufacturing process than IgG Fc.
Some of the physicochemical parameters of the FcRn-targeted NPs could also be further
optimized to improve the efficacy of the system, such as the IgG Fc surface density and the
NP size. Preliminary experiments indicated that the IgG Fc surface density affected the
efficacy of the NPs, but that could have been due to several reasons, such as changes in the
mucus penetration properties of the NPs, changes in intracellular trafficking, or altered
biodistribution after absorption. A better understanding of the mechanism or mechanisms
controlling this behavior would enable improved engineering of the system. Studies of
insulin encapsulation in NPs have shown that using different formulation methods results in
greater insulin loads, but at the cost of larger particle sizes that may reduce the efficiency of
absorption. Studying the trade-off between particle size, insulin encapsulation, and
absorption efficiency may reveal an optimal particle size that balances insulin load with
absorption efficiency.
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The FcRn-targeted NPs could also be evaluated for drug delivery across other cellular
barriers known to express FcRn, such as the vascular endothelium, blood-brain barrier,
kidneys, liver, and lungs (6). In particular, pulmonary administration is another convenient
route of administration that IgG Fc fusion proteins have had significant success with and
could be evaluated using FcRn-targeted NPs (7, 8). Another promising application is
vaccination. Studies using IgG Fc fused with herpes simplex virus type-2 (HSV-2)
glycoprotein gD demonstrated efficient immune responses after intranasal immunization
(9). Using FcRn-targeted NPs for mucosal immunization could be very effective, especially
since multiple antigens could be encapsulated in a single NP. Finally, another interesting
application involves using IgG antibodies as dual-targeting ligands. The Fab region of
antibodies is involved in binding to antigens and could be used to target NPs to specific
tissues, such as tumor cells. Conjugating whole IgG molecules to NPs could allow the Fc
portion to target the FcRn for oral administration while the Fab portion could target the NPs
to a specific tissue after absorption. This would take significant engineering of both the
ligand and NPs to be successful, but could potentially be a means to administer tumor-
targeted NPs orally.
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